{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":1073,"total_is_capped":false,"direct_labels_cover":5,"predictions_cover":1073,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"4bcee9d87cb6","filters":{"topic":"Colorectal Cancer Treatments and Studies"}},"results":[{"id":"W2155311724","doi":"10.1056/nejmoa0804385","title":"<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer","year":2008,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3597,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Cetuximab; Medicine; Colorectal cancer; Hazard ratio; Internal medicine; Oncology; Progression-free survival; Cancer; Exon; Confidence interval; Chemotherapy; Gene; Biology; Genetics","authors":[{"name":"Christos S. Karapetis","is_ca":false},{"name":"Shirin Khambata‐Ford","is_ca":false},{"name":"Derek J. Jonker","is_ca":true},{"name":"Chris J. O’Callaghan","is_ca":true},{"name":"Dongsheng Tu","is_ca":true},{"name":"Niall C. Tebbutt","is_ca":false},{"name":"R. J. Simes","is_ca":false},{"name":"Haji Chalchal","is_ca":false},{"name":"Jeremy Shapiro","is_ca":false},{"name":"Sonia Robitaille","is_ca":true},{"name":"Timothy Price","is_ca":false},{"name":"Lois E. Shepherd","is_ca":true},{"name":"Heather‐Jane Au","is_ca":false},{"name":"Christiane Langer","is_ca":false},{"name":"Malcolm J. Moore","is_ca":false},{"name":"John Zalcberg","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01824294315453895,"gpt":0.2893600566152159,"spread":0.2711171134606769,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006015174,0.000148256,0.0004887357,0.0001880998,0.0001177279,0.000213697,0.0001141683,0.000299421,0.0007977437],"category_scores_gemma":[0.00133776,0.00007928617,0.0003355962,0.0001522014,0.0001979919,0.0001059326,0.0001184821,0.0003702768,0.00006101379],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000324332,"about_ca_system_score_gemma":0.0003150093,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008134805,"about_ca_topic_score_gemma":0.001478429,"domain_scores_codex":[0.9997723,0.0000941211,0.00001646334,0.00003398239,0.00005292828,0.00003024458],"domain_scores_gemma":[0.9991937,0.0003637343,0.0002237822,0.00001999071,0.00003246404,0.0001662207],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.07707632,0.001272545,0.7980063,0.0006413269,0.001939395,0.0008205646,0.0001127307,0.004286685,0.02365796,0.0001775547,0.001447634,0.09056102],"study_design_scores_gemma":[0.001875531,0.007983922,0.9825802,0.00005345222,0.0006891565,0.0009217682,0.0000371928,0.002570478,0.001855628,0.0002470762,0.001171315,0.00001408923],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973464,0.001986309,0.00006233417,0.0001982074,0.00001331243,0.00001299747,0.00004204395,0.000003708097,0.0003346645],"genre_scores_gemma":[0.9994511,0.0002696532,0.00006949931,0.00006896471,0.00002191664,0.000004811848,0.00006025779,7.025017e-7,0.00005311477],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008134805,"threshold_uncertainty_score":0.003181159,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2314927739","doi":"10.1056/nejm200009283431302","title":"Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer","year":2000,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3010,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Irinotecan; Medicine; Fluorouracil; Bolus (digestion); Colorectal cancer; Chemotherapy; Internal medicine; Gastroenterology; Surgery; Cancer","authors":[{"name":"Leonard B. Saltz","is_ca":false},{"name":"John V. Cox","is_ca":false},{"name":"Charles D. Blanke","is_ca":false},{"name":"Lee S. Rosen","is_ca":false},{"name":"Louis Fehrenbacher","is_ca":false},{"name":"Malcolm J. Moore","is_ca":false},{"name":"Jean A. Maroun","is_ca":true},{"name":"Stephen P. Ackland","is_ca":false},{"name":"Paula K. Locker","is_ca":false},{"name":"Nicoletta Pirotta","is_ca":false},{"name":"Gary Elfring","is_ca":false},{"name":"Langdon L. Miller","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03290594841131935,"gpt":0.3246259538774529,"spread":0.2917200054661335,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001254062,0.0004494963,0.001367637,0.0003438221,0.0002592984,0.0003402687,0.0004237332,0.000468619,0.002662165],"category_scores_gemma":[0.001015678,0.0001993469,0.0009577751,0.0004406012,0.0004710722,0.0002796796,0.0002421183,0.000901561,0.0003035042],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007748544,"about_ca_system_score_gemma":0.001420129,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007840097,"about_ca_topic_score_gemma":0.002465489,"domain_scores_codex":[0.9993885,0.0003509074,0.00004265366,0.00006853625,0.00008303183,0.00006633886],"domain_scores_gemma":[0.9994037,0.0001610545,0.0001178313,0.00002652726,0.00002177813,0.0002690904],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8152265,0.008153515,0.01535602,0.001402187,0.002271681,0.0002573448,0.0000575568,0.002884654,0.017986,0.000349803,0.001622615,0.1344322],"study_design_scores_gemma":[0.3938846,0.5351316,0.05287946,0.0001470193,0.002285336,0.001270983,0.00004819025,0.002534063,0.005911075,0.0003695777,0.005509938,0.00002817111],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989169,0.007965272,0.0003365267,0.0003818478,0.0001253654,0.0007696021,0.000201664,0.00002357184,0.001027135],"genre_scores_gemma":[0.9944608,0.003011601,0.0008679578,0.0002293033,0.0002003975,0.000400499,0.0002731856,0.000003848573,0.0005524041],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002662165,"threshold_uncertainty_score":0.008905768,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2143743735","doi":"10.1200/jco.2007.14.9930","title":"Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2963,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Bevacizumab; Medicine; Oxaliplatin; FOLFOX; Folinic acid; Internal medicine; Colorectal cancer; Oncology; Capecitabine; Clinical endpoint; Chemotherapy; Placebo; Hazard ratio; Progression-free survival; Surgery; Randomized controlled trial; Cancer; Confidence interval; Pathology","authors":[{"name":"Leonard B. Saltz","is_ca":true},{"name":"Stephen Clarke","is_ca":true},{"name":"Eduardo Díaz‐Rubio","is_ca":true},{"name":"Werner Scheithauer","is_ca":true},{"name":"Arié Figer","is_ca":true},{"name":"Ralph Wong","is_ca":true},{"name":"Sheryl Koski","is_ca":true},{"name":"Mikhail Lichinitser","is_ca":true},{"name":"Tsai‐Shen Yang","is_ca":true},{"name":"Fernando Rivera","is_ca":true},{"name":"Félix Couture","is_ca":true},{"name":"Florin Sirzén","is_ca":true},{"name":"Jim Cassidy","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1003262096290122,"gpt":0.4668804551886769,"spread":0.3665542455596647,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002346284,0.001454065,0.003273105,0.0005358372,0.0003781448,0.001301826,0.001022422,0.00173196,0.00411129],"category_scores_gemma":[0.001700549,0.0007831574,0.001544145,0.000614836,0.001124878,0.0008167692,0.0003863775,0.002349879,0.0007631545],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001122926,"about_ca_system_score_gemma":0.00165285,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009825545,"about_ca_topic_score_gemma":0.002858041,"domain_scores_codex":[0.999006,0.0006085928,0.00004933999,0.0001287725,0.00009596658,0.0001114261],"domain_scores_gemma":[0.9990342,0.0002167275,0.0002555952,0.0000693472,0.00006744283,0.0003567423],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9409665,0.02153045,0.0009437883,0.0008912999,0.001393293,0.00007729983,0.00004971489,0.0005513667,0.005887782,0.00008662324,0.0009600062,0.02666187],"study_design_scores_gemma":[0.8990873,0.09830515,0.0009934601,0.00003007661,0.0003524858,0.00003540347,0.000007860916,0.0003702179,0.000298949,0.00004549448,0.0004647953,0.0000088584],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9834124,0.007655781,0.0008734933,0.0007160083,0.0006110051,0.004603819,0.0006331938,0.0001228493,0.001371464],"genre_scores_gemma":[0.9800152,0.006176476,0.002342877,0.001245621,0.0007899663,0.006121652,0.001052889,0.0000340009,0.002221186],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00411129,"threshold_uncertainty_score":0.01375365,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2115790682","doi":"10.1056/nejmoa071834","title":"Cetuximab for the Treatment of Colorectal Cancer","year":2007,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1806,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lakeridge Health; Sunnybrook Health Science Centre; Queen's University; Ottawa Hospital; St. Boniface Hospital; University of Ottawa","funders":"","keywords":"Cetuximab; Medicine; Irinotecan; Hazard ratio; Internal medicine; Colorectal cancer; Oxaliplatin; Oncology; Confidence interval; Cancer","authors":[{"name":"Derek J. Jonker","is_ca":true},{"name":"Chris J. O’Callaghan","is_ca":true},{"name":"Christos S. Karapetis","is_ca":false},{"name":"John Zalcberg","is_ca":false},{"name":"Dongsheng Tu","is_ca":true},{"name":"Scott Berry","is_ca":true},{"name":"Marianne Krahn","is_ca":true},{"name":"Timothy Price","is_ca":false},{"name":"R. J. Simes","is_ca":false},{"name":"Niall C. Tebbutt","is_ca":false},{"name":"Guy van Hazel","is_ca":false},{"name":"Christiane Langer","is_ca":false},{"name":"Malcolm J. Moore","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03249577843555444,"gpt":0.3453493300105736,"spread":0.3128535515750191,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003063733,0.0001784017,0.0002352017,0.0001911542,0.0001455266,0.0001577112,0.000163389,0.000201844,0.002366002],"category_scores_gemma":[0.0004193608,0.00003694842,0.0001732335,0.0001545802,0.0001019726,0.00008131149,0.0002082475,0.0004465603,0.0005382429],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004913768,"about_ca_system_score_gemma":0.0004550634,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007421771,"about_ca_topic_score_gemma":0.001979696,"domain_scores_codex":[0.9998933,0.00003106159,0.000007214688,0.00001311818,0.00003688511,0.00001840772],"domain_scores_gemma":[0.999885,0.00002224955,0.00003869754,0.000004982274,0.00001634192,0.0000326919],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007871022,0.0005744767,0.01441374,0.002414394,0.000466179,0.001306645,0.00009335858,0.001271998,0.02908476,0.001947441,0.03640082,0.9041552],"study_design_scores_gemma":[0.01122945,0.01522556,0.1849073,0.001919122,0.001405162,0.01616963,0.0000928602,0.005166886,0.02850225,0.003109046,0.7322109,0.00006177817],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.4743633,0.4660928,0.005146483,0.01525016,0.002095452,0.000721892,0.0006697837,0.0002615712,0.03539858],"genre_scores_gemma":[0.9084242,0.07100756,0.003618273,0.003559038,0.0008259522,0.0002033699,0.0008994213,0.00001638298,0.01144582],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.002366002,"threshold_uncertainty_score":0.00791508,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2146161922","doi":"10.1056/nejmoa043116","title":"Capecitabine as Adjuvant Treatment for Stage III Colon Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1247,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Capecitabine; Medicine; Fluorouracil; Hazard ratio; Internal medicine; Colorectal cancer; Regimen; Clinical endpoint; Bolus (digestion); Adverse effect; Gastroenterology; Oncology; Adjuvant; Surgery; Confidence interval; Chemotherapy; Cancer; Randomized controlled trial","authors":[{"name":"Chris Twelves","is_ca":false},{"name":"A. Wong","is_ca":false},{"name":"Marek P. Nowacki","is_ca":false},{"name":"Markus Abt","is_ca":false},{"name":"Howard A. Burris","is_ca":false},{"name":"Alfredo Carrato","is_ca":false},{"name":"Jim Cassidy","is_ca":false},{"name":"Andrés Cervantes","is_ca":false},{"name":"Jan Fagerberg","is_ca":false},{"name":"Vassilis Georgoulias","is_ca":false},{"name":"Fares Husseini","is_ca":false},{"name":"Duncan I. Jodrell","is_ca":false},{"name":"P. Koralewski","is_ca":false},{"name":"H. Kröning","is_ca":false},{"name":"Jean A. Maroun","is_ca":true},{"name":"Norbert Marschner","is_ca":false},{"name":"Joseph McKendrick","is_ca":false},{"name":"Marek Pawlicki","is_ca":false},{"name":"Riccardo Rosso","is_ca":false},{"name":"Johannes Schüller","is_ca":false},{"name":"Jean‐François Seitz","is_ca":false},{"name":"Borut Štabuc","is_ca":false},{"name":"Jerzy Tujakowski","is_ca":false},{"name":"Guy van Hazel","is_ca":false},{"name":"J. Załuski","is_ca":false},{"name":"Werner Scheithauer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03438742929994011,"gpt":0.3506999515904616,"spread":0.3163125222905215,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003134431,0.0001716421,0.0004408283,0.0001495244,0.000112073,0.0001649685,0.0001210298,0.0001512498,0.001867402],"category_scores_gemma":[0.0006555567,0.00004869619,0.0002342513,0.0001908516,0.0001437233,0.00006727561,0.0000916663,0.0004650749,0.0001867671],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003637867,"about_ca_system_score_gemma":0.0005044321,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00066111,"about_ca_topic_score_gemma":0.002534134,"domain_scores_codex":[0.9998955,0.00005453758,0.000006843511,0.00001048376,0.00001906944,0.00001369559],"domain_scores_gemma":[0.9997992,0.00005661749,0.00006066748,0.000009145193,0.00001124039,0.00006322049],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.09316611,0.003181626,0.02653037,0.002937956,0.0006672448,0.00137892,0.0001260863,0.002729033,0.0263769,0.0009908185,0.009703343,0.8322117],"study_design_scores_gemma":[0.1740306,0.3709463,0.2839016,0.002593921,0.003301729,0.01174921,0.0001861406,0.005363714,0.02061327,0.00287217,0.1243619,0.00007946334],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9187503,0.07183526,0.0009786231,0.001252609,0.000334426,0.0006355447,0.0001947165,0.0000376614,0.005980925],"genre_scores_gemma":[0.9800788,0.0164077,0.001020561,0.0004416017,0.0001612594,0.0002056678,0.000210567,0.000004749157,0.00146924],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001867402,"threshold_uncertainty_score":0.006247103,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2121847974","doi":"10.1016/s1470-2045(15)70127-0","title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":955,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Bevacizumab; FOLFIRI; Ramucirumab; Medicine; Oxaliplatin; Oncology; Internal medicine; Colorectal cancer; Second-line therapy; Placebo; Chemotherapy; Overall survival; Cancer; Pathology","authors":[{"name":"Josep Tabernero","is_ca":false},{"name":"Takayuki Yoshino","is_ca":false},{"name":"Allen Lee Cohn","is_ca":false},{"name":"Radka Obermannová","is_ca":false},{"name":"G. Bodoky","is_ca":false},{"name":"Rocio García‐Carbonero","is_ca":false},{"name":"Tudor–Eliade Ciuleanu","is_ca":false},{"name":"David C. Portnoy","is_ca":false},{"name":"Eric Van Cutsem","is_ca":false},{"name":"Axel Grothey","is_ca":false},{"name":"Jana Prausová","is_ca":false},{"name":"Pilar García‐Alfonso","is_ca":false},{"name":"Kentaro Yamazaki","is_ca":false},{"name":"Philip R. Clingan","is_ca":false},{"name":"Sara Lonardi","is_ca":false},{"name":"Tae Won Kim","is_ca":false},{"name":"Lorinda Simms","is_ca":true},{"name":"Shao-Chun Chang","is_ca":false},{"name":"Federico Nasroulah","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09086894514201639,"gpt":0.3537783983077336,"spread":0.2629094531657172,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002070412,0.002038846,0.00483002,0.0006030865,0.0004173464,0.001317689,0.001087958,0.001863766,0.003193644],"category_scores_gemma":[0.001695952,0.001007077,0.002957509,0.0004703534,0.001025974,0.001545831,0.0004215138,0.003710777,0.0007649325],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000934109,"about_ca_system_score_gemma":0.0009033749,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00114289,"about_ca_topic_score_gemma":0.002649689,"domain_scores_codex":[0.9991757,0.0004282208,0.00005232747,0.0001462486,0.00004481807,0.0001526881],"domain_scores_gemma":[0.9991936,0.0002245014,0.0001944329,0.0000759707,0.00004690429,0.0002645896],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.981985,0.004130179,0.0003976224,0.0003377922,0.0007898417,0.00002854925,0.00004986785,0.0002283368,0.001815134,0.00003342692,0.0002489949,0.009955158],"study_design_scores_gemma":[0.8600777,0.1354023,0.002375284,0.00002691849,0.0007393245,0.00004086699,0.00003224092,0.0004282811,0.0004730174,0.00006676002,0.0003147224,0.00002257684],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920056,0.004682973,0.0002975839,0.0003582068,0.000444338,0.0008280145,0.0003014934,0.0001018623,0.0009798459],"genre_scores_gemma":[0.9942497,0.001778046,0.0006662597,0.000438061,0.0003494186,0.0006369009,0.0003741067,0.00001609198,0.001491356],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00483002,"threshold_uncertainty_score":0.01094949,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2712978371","doi":"10.1001/jama.2017.7105","title":"Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer","year":2017,"lang":"en","type":"article","venue":"JAMA","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":893,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Bevacizumab; Cetuximab; FOLFIRI; Irinotecan; Regimen; KRAS; Internal medicine; Oncology; Oxaliplatin; Colorectal cancer; Chemotherapy regimen; Chemotherapy; Cancer","authors":[{"name":"Alan P. Venook","is_ca":false},{"name":"Donna Niedzwiecki","is_ca":false},{"name":"Heinz‐Josef Lenz","is_ca":false},{"name":"Federico Innocenti","is_ca":false},{"name":"Briant Fruth","is_ca":false},{"name":"Jeffrey A. Meyerhardt","is_ca":false},{"name":"Deborah Schrag","is_ca":false},{"name":"Claire Greene","is_ca":false},{"name":"Bert H. O’Neil","is_ca":false},{"name":"James N. Atkins","is_ca":false},{"name":"Scott Berry","is_ca":true},{"name":"Blasé N. Polite","is_ca":false},{"name":"Eileen M. O’Reilly","is_ca":false},{"name":"Richard M. Goldberg","is_ca":false},{"name":"Howard S. Höchster","is_ca":false},{"name":"Richard L. Schilsky","is_ca":false},{"name":"Monica M. Bertagnolli","is_ca":false},{"name":"Anthony B. El-Khoueiry","is_ca":false},{"name":"Peter J. Watson","is_ca":false},{"name":"Al B. Benson","is_ca":false},{"name":"Daniel Mulkerin","is_ca":false},{"name":"Robert J. Mayer","is_ca":false},{"name":"Charles D. Blanke","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01304249158422767,"gpt":0.2971890219946865,"spread":0.2841465304104588,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007273687,0.0004027499,0.000894089,0.0002483328,0.0002266657,0.0004577647,0.0003511308,0.0006108141,0.001674149],"category_scores_gemma":[0.001361954,0.0001762855,0.001220077,0.0001850752,0.0002699055,0.0004504731,0.0002256197,0.001159998,0.0001673865],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001062048,"about_ca_system_score_gemma":0.0008479151,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001729499,"about_ca_topic_score_gemma":0.009351091,"domain_scores_codex":[0.9997546,0.00009988718,0.00001672591,0.00004515194,0.00002953502,0.00005413016],"domain_scores_gemma":[0.9991804,0.0002017699,0.0002269616,0.00003270621,0.00003849322,0.0003197114],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.703579,0.01903904,0.07196855,0.0009460256,0.00290511,0.0001800844,0.000167677,0.003461709,0.01015509,0.0001316292,0.003043159,0.1844229],"study_design_scores_gemma":[0.1349394,0.5289024,0.3199657,0.0002752884,0.003651203,0.0005350647,0.0001442358,0.004567781,0.003973321,0.0002575992,0.002729445,0.00005865312],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961092,0.002626363,0.00006196464,0.0002456679,0.00008444874,0.00009678311,0.0001369385,0.00001450806,0.0006241521],"genre_scores_gemma":[0.998091,0.0007866173,0.0001411705,0.0002650582,0.0000717201,0.00006693648,0.0002728973,0.000002568924,0.0003020116],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001729499,"threshold_uncertainty_score":0.007705748,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2132545630","doi":"10.1200/jco.2007.11.3357","title":"Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":857,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lakeridge Health","funders":"","keywords":"FOLFIRI; Medicine; Irinotecan; Bevacizumab; Internal medicine; Clinical endpoint; Colorectal cancer; Gastroenterology; Fluorouracil; Capecitabine; Surgery; Oncology; Randomized controlled trial; Chemotherapy; Cancer","authors":[{"name":"Charles S. Fuchs","is_ca":true},{"name":"John L. Marshall","is_ca":true},{"name":"Edith P. Mitchell","is_ca":true},{"name":"Rafal Wierzbicki","is_ca":true},{"name":"Vinod Ganju","is_ca":true},{"name":"Mark Jeffery","is_ca":true},{"name":"Joseph J. Schulz","is_ca":true},{"name":"Donald Richards","is_ca":true},{"name":"Raoudha Soufi‐Mahjoubi","is_ca":true},{"name":"Benjamin Wang","is_ca":true},{"name":"José Barrueco","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1741197648038616,"gpt":0.4876139936765206,"spread":0.3134942288726591,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002459605,0.001618722,0.004187194,0.0004535219,0.0005966239,0.001339072,0.0009988016,0.001949591,0.008072553],"category_scores_gemma":[0.002945481,0.0006761834,0.002122084,0.000513333,0.001040119,0.0007448921,0.0003722186,0.003070832,0.001089935],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001002476,"about_ca_system_score_gemma":0.002186356,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002123366,"about_ca_topic_score_gemma":0.005035304,"domain_scores_codex":[0.998915,0.0006331677,0.00007823303,0.0001732147,0.00008646874,0.0001139875],"domain_scores_gemma":[0.9982435,0.0005313418,0.0004320938,0.0001198421,0.0001367921,0.0005364745],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9907767,0.002543503,0.000254455,0.0003692528,0.0006569097,0.00001240374,0.00001526644,0.0001085233,0.0006166392,0.0000311507,0.0004299567,0.004185163],"study_design_scores_gemma":[0.984647,0.01402059,0.0005644796,0.00001560377,0.0003070354,0.000008207319,0.000004436752,0.0001081522,0.00008173774,0.0000215312,0.0002161193,0.000005105005],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9716291,0.01205565,0.0007922195,0.0009885769,0.001368591,0.007885664,0.00237631,0.0001754244,0.002728297],"genre_scores_gemma":[0.9768146,0.00590858,0.001763787,0.001827499,0.0009022342,0.006690582,0.002546237,0.00003912845,0.003507487],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008072553,"threshold_uncertainty_score":0.02700537,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1974365898","doi":"10.1001/jama.2010.1535","title":"Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab","year":2010,"lang":"en","type":"article","venue":"JAMA","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":747,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research; Ottawa Hospital","funders":"Associazione Italiana per la Ricerca sul Cancro; Celgene; AstraZeneca; Flinders University; Bristol-Myers Squibb; Vlaamse regering; Amgen","keywords":"Cetuximab; KRAS; Medicine; Colorectal cancer; Oncology; Internal medicine; Hazard ratio; Cancer; Confidence interval","authors":[{"name":"Wendy De Roock","is_ca":false},{"name":"Derek J. Jonker","is_ca":true},{"name":"Federica Di Nicolantonio","is_ca":false},{"name":"Andrea Sartore‐Bianchi","is_ca":false},{"name":"Dongsheng Tu","is_ca":true},{"name":"Salvatore Siena","is_ca":false},{"name":"Simona Lamba","is_ca":false},{"name":"Sabrina Arena","is_ca":false},{"name":"Milo Frattini","is_ca":false},{"name":"Hubert Piessevaux","is_ca":false},{"name":"Eric Van Cutsem","is_ca":false},{"name":"Chris J. O’Callaghan","is_ca":true},{"name":"Shirin Khambata‐Ford","is_ca":false},{"name":"John Zalcberg","is_ca":false},{"name":"John Simes","is_ca":false},{"name":"Christos S. Karapetis","is_ca":false},{"name":"Alberto Bardelli","is_ca":false},{"name":"Sabine Tejpar","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.00824824298040603,"gpt":0.2655267310294429,"spread":0.2572784880490368,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007880669,0.0001976892,0.0005985304,0.0004178799,0.0002086414,0.0003218097,0.0002015675,0.0004595354,0.0007738461],"category_scores_gemma":[0.001802967,0.0001398153,0.000603941,0.0005098833,0.0001986231,0.0001692656,0.0002319926,0.0003697935,0.00008724222],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003170436,"about_ca_system_score_gemma":0.0003102246,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001128278,"about_ca_topic_score_gemma":0.002160966,"domain_scores_codex":[0.9995578,0.0001615149,0.00005532419,0.0001004297,0.00007635859,0.00004857634],"domain_scores_gemma":[0.9985056,0.0004308425,0.0006871858,0.00008224086,0.00008025328,0.0002139379],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002753875,0.00006003636,0.9925548,0.00002397433,0.0004550862,0.0001258738,0.00001785398,0.0002442014,0.00106503,0.000006351522,0.00007771839,0.002615139],"study_design_scores_gemma":[0.000116127,0.0008066728,0.9974381,0.000007562406,0.000258273,0.0004441891,0.00002385055,0.0005114242,0.000239188,0.0000172078,0.0001322736,0.000005186237],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9993957,0.0003424734,0.0000430111,0.00002361428,0.000003090029,0.000004549388,0.00009745943,0.00000142784,0.00008865332],"genre_scores_gemma":[0.9996144,0.00006194883,0.00002858379,0.00001862018,0.000007648065,0.000005059056,0.0002329911,7.260746e-7,0.00003006577],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001128278,"threshold_uncertainty_score":0.004167736,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2168579528","doi":"10.1016/s1470-2045(13)70154-2","title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":654,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"National Institutes of Health; Institute of Cancer Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; F. Hoffmann-La Roche","keywords":"Capecitabine; Medicine; Bevacizumab; Internal medicine; Irinotecan; Colorectal cancer; Hazard ratio; Clinical endpoint; Oxaliplatin; Adverse effect; Oncology; Population; Cancer; Randomized controlled trial; Chemotherapy; Surgery; Confidence interval","authors":[{"name":"David Cunningham","is_ca":false},{"name":"István Láng","is_ca":false},{"name":"Eugenio Marcuello","is_ca":false},{"name":"Vito Lorusso","is_ca":false},{"name":"Janja Ocvirk","is_ca":false},{"name":"Dong Bok Shin","is_ca":false},{"name":"Derek J. Jonker","is_ca":true},{"name":"Stuart Osborne","is_ca":false},{"name":"Niko Andre","is_ca":false},{"name":"Daniel Waterkamp","is_ca":false},{"name":"Mark Saunders","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06574882485102473,"gpt":0.374869717678169,"spread":0.3091208928271442,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00152707,0.001737979,0.00262498,0.0003919885,0.0003949429,0.0009971159,0.0006356621,0.001538756,0.006505406],"category_scores_gemma":[0.001790587,0.0006149008,0.002188496,0.0003968919,0.001014453,0.001265325,0.0004075591,0.002771995,0.0007569253],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008550219,"about_ca_system_score_gemma":0.0007828015,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001618506,"about_ca_topic_score_gemma":0.004222525,"domain_scores_codex":[0.9995677,0.0002239782,0.0000259264,0.00008095763,0.00002617151,0.00007515049],"domain_scores_gemma":[0.9991174,0.0003064544,0.0001811001,0.00004976886,0.00004017986,0.0003050233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9835082,0.002509728,0.0004421093,0.0004045436,0.0007200863,0.00003274549,0.00005028089,0.0002631286,0.001277922,0.00007914792,0.0005701993,0.01014191],"study_design_scores_gemma":[0.9383504,0.05860614,0.00163392,0.00003100938,0.000369788,0.00003104717,0.00002552666,0.0002748515,0.0001430221,0.0001139025,0.0004080393,0.00001220268],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894263,0.005305968,0.0003718802,0.0006938377,0.0005516729,0.001373427,0.0006956541,0.00006273994,0.001518626],"genre_scores_gemma":[0.9880897,0.003416398,0.001098911,0.0009799361,0.0004954064,0.001534993,0.0009638966,0.00001792814,0.003402679],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006505406,"threshold_uncertainty_score":0.02176273,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2123133140","doi":"10.1200/jco.2003.11.126","title":"Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":645,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; Sanofi","keywords":"Medicine; Oxaliplatin; Irinotecan; Fluorouracil; Internal medicine; Colorectal cancer; Gastroenterology; Interim analysis; Bolus (digestion); Oncology; Chemotherapy; Surgery; Cancer; Clinical trial","authors":[{"name":"Mace L. Rothenberg","is_ca":true},{"name":"Amit M. Oza","is_ca":true},{"name":"Robert Bigelow","is_ca":true},{"name":"Jordan Berlin","is_ca":true},{"name":"John L. Marshall","is_ca":true},{"name":"Ramesh K. Ramanathan","is_ca":true},{"name":"Lowell L. Hart","is_ca":true},{"name":"Sunil Gupta","is_ca":true},{"name":"Carlos A. Garay","is_ca":true},{"name":"Brent Burger","is_ca":true},{"name":"N Le Bail","is_ca":true},{"name":"Daniel G. Haller","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06821672524614635,"gpt":0.421301268873285,"spread":0.3530845436271386,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002866124,0.001178623,0.002136734,0.0004291502,0.0003563844,0.001048682,0.0008047191,0.001282319,0.003384128],"category_scores_gemma":[0.001882955,0.0004510879,0.001779336,0.0004283985,0.0008442835,0.0008439642,0.000325791,0.002442013,0.0006552828],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008092414,"about_ca_system_score_gemma":0.001251504,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006176193,"about_ca_topic_score_gemma":0.001877695,"domain_scores_codex":[0.9990149,0.0006363885,0.00005615536,0.0001171475,0.00005000647,0.0001253588],"domain_scores_gemma":[0.9984712,0.0004996161,0.0003414642,0.0001030838,0.00005758132,0.0005269499],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9625534,0.007076633,0.001962875,0.0002247465,0.000845509,0.00005010963,0.00005987456,0.0003508057,0.001990145,0.00005613389,0.0005151442,0.02431445],"study_design_scores_gemma":[0.796941,0.1957691,0.004869753,0.00003182735,0.0006137205,0.00007347066,0.00002021509,0.0005254102,0.0005474258,0.0000839058,0.0005108792,0.00001329884],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942947,0.002876676,0.0002437138,0.0004545707,0.0001921791,0.0006454052,0.0003090274,0.00004467776,0.0009391262],"genre_scores_gemma":[0.9948344,0.001316632,0.0007601549,0.0006068256,0.000318827,0.0007204339,0.000591441,0.00001010847,0.0008411412],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003384128,"threshold_uncertainty_score":0.01515764,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2159179344","doi":"10.1093/annonc/mdu141","title":"Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":604,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Credit Valley Hospital; Mount Sinai Hospital","funders":"","keywords":"Medicine; Panitumumab; KRAS; Internal medicine; Hazard ratio; Colorectal cancer; Clinical endpoint; Randomized controlled trial; Oxaliplatin; Confidence interval; Oncology; Adverse effect; Gastroenterology; Cancer","authors":[{"name":"J.-Y. Douillard","is_ca":false},{"name":"Salvatore Siena","is_ca":false},{"name":"J Cassidy","is_ca":false},{"name":"Josep Tabernero","is_ca":false},{"name":"Ronald L. Burkes","is_ca":true},{"name":"Mario Barugel","is_ca":false},{"name":"Yves Humblet","is_ca":false},{"name":"G. Bodoky","is_ca":false},{"name":"David Cunningham","is_ca":false},{"name":"Jacek Jassem","is_ca":false},{"name":"Fernando Rivera","is_ca":false},{"name":"Ilona Kocáková","is_ca":false},{"name":"Paul Ruff","is_ca":false},{"name":"Maria Błasińska-Morawiec","is_ca":false},{"name":"Martin Šmakal","is_ca":false},{"name":"J.-L. Canon","is_ca":false},{"name":"M. Rother","is_ca":true},{"name":"Kelly S. Oliner","is_ca":false},{"name":"Ying Tian","is_ca":false},{"name":"Feng Xu","is_ca":false},{"name":"R. Sidhu","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1282057758737968,"gpt":0.4285832052192958,"spread":0.300377429345499,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002749576,0.001799158,0.0032888,0.00033863,0.0006186562,0.001210291,0.001102072,0.001422071,0.008035826],"category_scores_gemma":[0.002376224,0.000938564,0.002956882,0.0002845508,0.00117365,0.001371698,0.0005165191,0.003804814,0.001250345],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001072505,"about_ca_system_score_gemma":0.001883133,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001695704,"about_ca_topic_score_gemma":0.004122618,"domain_scores_codex":[0.999313,0.0004029851,0.0000272498,0.00009682172,0.00004481991,0.0001151315],"domain_scores_gemma":[0.9987716,0.0003740763,0.0002023046,0.0001438338,0.0000934323,0.0004147273],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9672286,0.003189744,0.0006070861,0.0005055342,0.001153576,0.00005465262,0.00005686395,0.0005741196,0.002738149,0.000141588,0.003407371,0.02034275],"study_design_scores_gemma":[0.9494562,0.0445363,0.002515943,0.000029931,0.0008896072,0.00005650374,0.00001795671,0.0002024006,0.0005355497,0.0002247449,0.001519316,0.00001541127],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9638173,0.008861868,0.002182416,0.003325263,0.001236773,0.006244409,0.007162884,0.000498326,0.006670706],"genre_scores_gemma":[0.9604988,0.004461812,0.006116061,0.003448114,0.0008424824,0.005078377,0.0077849,0.0001751025,0.01159442],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008035826,"threshold_uncertainty_score":0.02688253,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2165741055","doi":"10.1093/annonc/mdp233","title":"Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":534,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research; Roche","keywords":"Medicine; Bevacizumab; Irinotecan; Oxaliplatin; Internal medicine; Capecitabine; FOLFOX; FOLFIRI; Colorectal cancer; Oncology; Fluorouracil; Surgery; Chemotherapy; Chemotherapy regimen; Cancer","authors":[{"name":"Eric Van Cutsem","is_ca":false},{"name":"Fernando Rivera","is_ca":false},{"name":"Scott Berry","is_ca":true},{"name":"Albrecht Kretzschmar","is_ca":false},{"name":"M. Michael","is_ca":false},{"name":"M. Mazier","is_ca":false},{"name":"J.-L. Canon","is_ca":false},{"name":"Vassilis Georgoulias","is_ca":false},{"name":"Marc Peeters","is_ca":false},{"name":"John Bridgewater","is_ca":false},{"name":"David Cunningham","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05728466980328281,"gpt":0.3809595963763208,"spread":0.323674926573038,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002179219,0.0006435963,0.002142747,0.0004279369,0.0002984489,0.0007785952,0.0006955317,0.001108158,0.001238403],"category_scores_gemma":[0.002783928,0.0003472746,0.002179345,0.0005055683,0.0005470341,0.001169418,0.000326214,0.002361152,0.0002376299],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001135545,"about_ca_system_score_gemma":0.0008480404,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001105275,"about_ca_topic_score_gemma":0.002032244,"domain_scores_codex":[0.999024,0.0004299177,0.00005813111,0.0001589957,0.0002019266,0.0001269973],"domain_scores_gemma":[0.9981389,0.000549062,0.0006055198,0.0001586954,0.0001021741,0.0004455423],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8576065,0.009757062,0.03449557,0.0005276633,0.005052278,0.000115152,0.0001022012,0.00148933,0.005463339,0.0001295512,0.0009465314,0.08431491],"study_design_scores_gemma":[0.2451988,0.5486308,0.1897037,0.0001227317,0.00685022,0.0005941786,0.0001088677,0.002458547,0.002790892,0.0004005748,0.003051642,0.00008897481],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994272,0.004516724,0.0001122766,0.0001228157,0.00004985733,0.00006978438,0.0002978658,0.00001324226,0.0005455036],"genre_scores_gemma":[0.9970354,0.001240729,0.0001704241,0.0001883052,0.0001650393,0.00006156244,0.0006157867,0.00000855972,0.0005141836],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002179219,"threshold_uncertainty_score":0.01152498,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2098499757","doi":"10.1016/s1470-2045(12)70509-0","title":"Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":526,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech","keywords":"Bevacizumab; Medicine; Oxaliplatin; Capecitabine; Colorectal cancer; Clinical endpoint; Internal medicine; Bolus (digestion); Chemotherapy; Fluorouracil; Surgery; Gastroenterology; Phases of clinical research; Randomized controlled trial; Cancer","authors":[{"name":"Aimery de Gramont","is_ca":false},{"name":"Eric Van Cutsem","is_ca":false},{"name":"Hans‐Joachim Schmoll","is_ca":false},{"name":"Josep Tabernero","is_ca":false},{"name":"Stephen Clarke","is_ca":false},{"name":"Malcolm J. Moore","is_ca":true},{"name":"David Cunningham","is_ca":false},{"name":"Thomas H. Cartwright","is_ca":false},{"name":"J. Randolph Hecht","is_ca":false},{"name":"Fernando Rivera","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"G. Bodoky","is_ca":false},{"name":"Ramón Salazar","is_ca":false},{"name":"Einat Shacham‐Shmueli","is_ca":false},{"name":"Emilio Bajetta","is_ca":false},{"name":"Martina Makrutzki","is_ca":false},{"name":"Aijing Shang","is_ca":false},{"name":"Thierry André","is_ca":false},{"name":"Paulo M. Hoff","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0801800099192156,"gpt":0.4280330432983145,"spread":0.3478530333790989,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002760219,0.002157807,0.003918567,0.0005036243,0.0005314476,0.001459597,0.001121197,0.002349406,0.008428083],"category_scores_gemma":[0.003001192,0.0009565841,0.003544991,0.0006957017,0.00142556,0.001401534,0.0005844925,0.003721613,0.001039698],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001093478,"about_ca_system_score_gemma":0.001411032,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002069714,"about_ca_topic_score_gemma":0.004233519,"domain_scores_codex":[0.9988494,0.0006590186,0.00008446281,0.0001862965,0.00007324775,0.0001476133],"domain_scores_gemma":[0.998688,0.0004480194,0.0003295511,0.0001109872,0.0000823954,0.0003409984],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9898084,0.001119239,0.0001356768,0.001080007,0.001191126,0.00001991386,0.00002945726,0.0001857415,0.0007686868,0.00009322778,0.0005442261,0.005024274],"study_design_scores_gemma":[0.9853923,0.01298063,0.0002959839,0.00004618052,0.000654464,0.00001167868,0.000008563386,0.0001054143,0.00007378584,0.00008727526,0.0003367915,0.000006979481],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9432797,0.03141207,0.002345658,0.002718192,0.003260269,0.009275374,0.002963135,0.0003112845,0.00443423],"genre_scores_gemma":[0.9625772,0.01274906,0.004153533,0.002479234,0.001099253,0.008784409,0.001908393,0.00006873673,0.006180256],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008428083,"threshold_uncertainty_score":0.02819479,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2138926750","doi":"10.1093/annonc/mdf089","title":"First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin","year":2002,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":524,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Capecitabine; Medicine; Internal medicine; Neutropenia; Fluorouracil; Gastroenterology; Regimen; Adverse effect; Colorectal cancer; Nausea; Febrile neutropenia; Oncology; Surgery; Cancer; Chemotherapy","authors":[{"name":"Jim Cassidy","is_ca":false},{"name":"Chris Twelves","is_ca":false},{"name":"Eric Van Cutsem","is_ca":false},{"name":"Paulo M. Hoff","is_ca":false},{"name":"Emilio Bajetta","is_ca":false},{"name":"Michael Boyer","is_ca":false},{"name":"R. Bugat","is_ca":false},{"name":"Ulrich Bürger","is_ca":false},{"name":"A. Garin","is_ca":false},{"name":"Ullrich Graeven","is_ca":false},{"name":"J. McKendrick","is_ca":false},{"name":"Jean A. Maroun","is_ca":true},{"name":"John L. Marshall","is_ca":false},{"name":"B Osterwalder","is_ca":false},{"name":"G. Pérez-Manga","is_ca":false},{"name":"R. Rosso","is_ca":false},{"name":"P. Rougier","is_ca":false},{"name":"Richard L. Schilsky","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09844456695473171,"gpt":0.3593883428312434,"spread":0.2609437758765117,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004167435,0.000242304,0.0007842096,0.0001582612,0.0001543656,0.0003728205,0.0001492013,0.0002653467,0.002590345],"category_scores_gemma":[0.001201555,0.0001086823,0.0004638532,0.0002565097,0.0001453476,0.0002389339,0.00009068826,0.000799269,0.0001681521],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000484679,"about_ca_system_score_gemma":0.0004822821,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007612914,"about_ca_topic_score_gemma":0.003012445,"domain_scores_codex":[0.9998701,0.00006426271,0.000007962581,0.00001260989,0.00002471073,0.00002039951],"domain_scores_gemma":[0.9995548,0.0001756709,0.0001292072,0.00002493392,0.00002099555,0.00009436807],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2851337,0.00359214,0.03523627,0.00152267,0.001637025,0.001003694,0.0001776952,0.002483671,0.07878125,0.0004072082,0.003302045,0.5867228],"study_design_scores_gemma":[0.06926914,0.3113296,0.5287437,0.0003976483,0.004271005,0.008413035,0.0002361678,0.00775369,0.0529368,0.0006849064,0.01587811,0.00008629637],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873355,0.01049045,0.0002960977,0.0002893975,0.00005554328,0.0000519262,0.0002095922,0.00002170932,0.0012499],"genre_scores_gemma":[0.9955204,0.00302027,0.0002744086,0.0001135395,0.00005453825,0.00001684512,0.0002684175,0.000008767535,0.0007228624],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002590345,"threshold_uncertainty_score":0.008665621,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2037339308","doi":"10.1200/jco.2007.11.2144","title":"Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":447,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Pfizer","keywords":"Medicine; Irinotecan; Fluorouracil; Bolus (digestion); Regimen; Colorectal cancer; Adjuvant; Internal medicine; Oncology; Toxicity; Adjuvant therapy; Surgery; Gastroenterology; Chemotherapy; Cancer","authors":[{"name":"Leonard B. Saltz","is_ca":true},{"name":"Donna Niedzwiecki","is_ca":true},{"name":"Donna Hollis","is_ca":true},{"name":"Richard M. Goldberg","is_ca":true},{"name":"Alexander Hantel","is_ca":true},{"name":"James P. Thomas","is_ca":true},{"name":"Anthony Fields","is_ca":true},{"name":"Robert J. Mayer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.178085407871939,"gpt":0.4903242408471618,"spread":0.3122388329752227,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003031878,0.0005424398,0.001514921,0.0003568101,0.0002513828,0.0004884553,0.0004558263,0.0006113281,0.002398982],"category_scores_gemma":[0.002132595,0.0002307495,0.00139257,0.0004564481,0.0006148246,0.000355219,0.000228344,0.001408509,0.0002548812],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001026008,"about_ca_system_score_gemma":0.001800064,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004538665,"about_ca_topic_score_gemma":0.01222179,"domain_scores_codex":[0.9990935,0.0005695097,0.00005407683,0.00007547287,0.0001236227,0.00008374098],"domain_scores_gemma":[0.9986838,0.0004597157,0.0002687383,0.0001064319,0.00008737254,0.0003939523],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8378502,0.01343827,0.006397907,0.0008721489,0.003567503,0.00008027918,0.0001051098,0.001487685,0.01465586,0.0001323769,0.001826067,0.1195866],"study_design_scores_gemma":[0.4746538,0.4524925,0.05572087,0.0001992561,0.006258343,0.0001974621,0.00007017844,0.001920895,0.004528765,0.0002507285,0.003670121,0.00003717947],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883081,0.008468688,0.0002228939,0.0006715762,0.0001051501,0.000382369,0.000387933,0.00002625352,0.001427116],"genre_scores_gemma":[0.9913409,0.004495139,0.0007111616,0.0007576871,0.0001599428,0.0001945129,0.0009283788,0.00001486051,0.001397432],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004538665,"threshold_uncertainty_score":0.01603431,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2084330540","doi":"10.1038/sj.bjc.6601676","title":"Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials","year":2004,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":398,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Capecitabine; Medicine; Internal medicine; Hazard ratio; Fluorouracil; Regimen; Confidence interval; Gastroenterology; Population; Proportional hazards model; Colorectal cancer; Oncology; Surgery; Chemotherapy; Cancer","authors":[{"name":"Eric Van Cutsem","is_ca":false},{"name":"Paulo M. Hoff","is_ca":false},{"name":"Peter Harper","is_ca":false},{"name":"Ronald M. Bukowski","is_ca":false},{"name":"David Cunningham","is_ca":false},{"name":"P Dufour","is_ca":false},{"name":"Ullrich Graeven","is_ca":false},{"name":"J Lokich","is_ca":false},{"name":"Stefan Madajewicz","is_ca":false},{"name":"Jean A. Maroun","is_ca":true},{"name":"John L. Marshall","is_ca":false},{"name":"Edith P. Mitchell","is_ca":false},{"name":"G. Pérez-Manga","is_ca":false},{"name":"P. Rougier","is_ca":false},{"name":"Wolff Schmiegel","is_ca":false},{"name":"Juergen Schöelmerich","is_ca":false},{"name":"Alberto Sobrero","is_ca":false},{"name":"Richard L. Schilsky","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1004104825505594,"gpt":0.4197499322979251,"spread":0.3193394497473658,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02063662,0.001323376,0.003823995,0.000599419,0.0002730068,0.001522272,0.0009237266,0.001651852,0.001507887],"category_scores_gemma":[0.02129958,0.0004067497,0.003536399,0.001328538,0.001280464,0.001097619,0.0009030053,0.001761148,0.0002469415],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001076626,"about_ca_system_score_gemma":0.001073532,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004542785,"about_ca_topic_score_gemma":0.001221189,"domain_scores_codex":[0.9846252,0.01277194,0.0009018266,0.0006660257,0.0007003437,0.0003346287],"domain_scores_gemma":[0.9855441,0.008472464,0.003530178,0.001235822,0.0004863891,0.0007309702],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.9154893,0.003047509,0.009674299,0.002387482,0.01366809,0.00009061756,0.0001663546,0.001433866,0.005645234,0.000200531,0.0004957221,0.04770106],"study_design_scores_gemma":[0.7548584,0.169641,0.04561358,0.0004858714,0.02034037,0.0003115441,0.0001281801,0.001752633,0.002369436,0.0006256077,0.003782735,0.00009061099],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9486176,0.0421535,0.003326769,0.0005796264,0.0001851951,0.002555552,0.001284686,0.00005937961,0.001237601],"genre_scores_gemma":[0.9812236,0.008817631,0.003112368,0.0007593737,0.0002352724,0.002706045,0.002691083,0.0000282999,0.0004264509],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02063662,"threshold_uncertainty_score":0.1091382,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1870066362","doi":"10.1200/jco.2004.03.104","title":"Modulation of Fluorouracil by Leucovorin in Patients With Advanced Colorectal Cancer: An Updated Meta-Analysis","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":387,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Folinic acid; Fluorouracil; Internal medicine; Colorectal cancer; Meta-analysis; Randomized controlled trial; Odds ratio; Oncology; Hazard ratio; Gastroenterology; Confidence interval; Cancer","authors":[{"name":"P. Thirion","is_ca":true},{"name":"Stefan Michiels","is_ca":false},{"name":"Jean‐Pierre Pignon","is_ca":false},{"name":"Marc Buyse","is_ca":false},{"name":"A.C. Braud","is_ca":false},{"name":"Robert W. Carlson","is_ca":false},{"name":"M. O’Connell","is_ca":false},{"name":"Penny Sargent","is_ca":false},{"name":"P Piedbois","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1748375784886754,"gpt":0.4978436670426455,"spread":0.3230060885539702,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01145107,0.002453958,0.01338754,0.003181677,0.0003922698,0.00225768,0.001544293,0.00166068,0.003111349],"category_scores_gemma":[0.01951858,0.001211255,0.03918401,0.004190018,0.0003647821,0.001208463,0.001015593,0.001802932,0.0002881358],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001397571,"about_ca_system_score_gemma":0.001133999,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005398744,"about_ca_topic_score_gemma":0.009389786,"domain_scores_codex":[0.9921307,0.004430363,0.001513601,0.0009652761,0.0007079282,0.0002520252],"domain_scores_gemma":[0.9898392,0.00713026,0.001533526,0.0006531078,0.0006437324,0.0002002957],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.006051855,0.00002523344,0.00606277,0.03078553,0.9499021,0.00009484716,0.00002816323,0.000775504,0.0003141109,0.00005626249,0.0004915575,0.005412161],"study_design_scores_gemma":[0.00120978,0.000194605,0.005019011,0.001069011,0.9913515,0.00006387035,0.00001066837,0.0002564772,0.00007822499,0.00007684583,0.000656481,0.00001353403],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.04274868,0.9514804,0.001784771,0.0005476764,0.0005346625,0.0002733076,0.001746993,0.0001147678,0.0007687453],"genre_scores_gemma":[0.7757015,0.2150596,0.003332043,0.001501924,0.0006009378,0.0006309298,0.002339516,0.0001031388,0.0007304201],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01338754,"threshold_uncertainty_score":0.06055981,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2142019712","doi":"10.1158/1078-0432.ccr-07-1061","title":"Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":366,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"National Cancer Institute; University of California, San Diego; National Institutes of Health","keywords":"Bendamustine; DNA damage; DNA repair; Biology; Nitrogen mustard; Mitotic catastrophe; Mechanism of action; Chlorambucil; Cancer research; DNA; Pharmacology; Chemotherapy; In vitro; Genetics; Leukemia; Chronic lymphocytic leukemia; Cyclophosphamide","authors":[{"name":"Lorenzo M. Leoni","is_ca":false},{"name":"Brandi Bailey","is_ca":false},{"name":"Jack Reifert","is_ca":false},{"name":"Heather Bendall","is_ca":false},{"name":"Robert W. Zeller","is_ca":false},{"name":"Jacques Corbeil","is_ca":true},{"name":"Gary Elliott","is_ca":false},{"name":"Christina C. Niemeyer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2350859728693352,"gpt":0.4859579457032853,"spread":0.2508719728339501,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001530789,0.0002712984,0.0002844325,0.0002730023,0.00009764824,0.0002314621,0.0001350671,0.0002684987,0.001445032],"category_scores_gemma":[0.0002124329,0.00008699166,0.0002555119,0.0001938228,0.0001617659,0.0001896527,0.0001223001,0.0003756452,0.0002769589],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002322872,"about_ca_system_score_gemma":0.0001263286,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002042857,"about_ca_topic_score_gemma":0.0005141804,"domain_scores_codex":[0.9998684,0.00002249638,0.00001322064,0.00003057772,0.00004403922,0.0000212511],"domain_scores_gemma":[0.9998838,0.00002445604,0.000040973,0.00001451185,0.00001681723,0.00001941163],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002440915,0.0000288816,0.00091354,0.00005463058,0.00001481749,0.00005970121,0.000007119218,0.0001955708,0.9930689,0.00008354848,0.0000283833,0.005300778],"study_design_scores_gemma":[0.00006300905,0.002124361,0.02307821,0.000009562608,0.00004072929,0.003010142,0.00001783328,0.0003370953,0.9667035,0.0001059643,0.004502575,0.000007045029],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877564,0.006305797,0.002876669,0.0001825693,0.00001818664,0.0000456734,0.000442568,0.0000673177,0.002304877],"genre_scores_gemma":[0.9923968,0.002304178,0.002081199,0.00008249239,0.00001218952,0.00002812466,0.001303015,0.00001529776,0.001776738],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001445032,"threshold_uncertainty_score":0.004834116,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1799482054","doi":"10.1016/j.ejca.2015.03.015","title":"Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":337,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CancerCare Manitoba; University Health Network; University of Toronto; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Cetuximab; Medicine; KRAS; Internal medicine; Colorectal cancer; Oncology; Hazard ratio; Proportional hazards model; Epidermal growth factor receptor; Refractory (planetary science); Splenic flexure; Cancer; Gastroenterology; Confidence interval; Colonoscopy; Biology","authors":[{"name":"Stephanie Yasmin Brule","is_ca":true},{"name":"Derek J. Jonker","is_ca":true},{"name":"Christos S. Karapetis","is_ca":false},{"name":"Chris J. O’Callaghan","is_ca":false},{"name":"Malcolm J. Moore","is_ca":true},{"name":"Ralph Wong","is_ca":true},{"name":"Niall C. Tebbutt","is_ca":false},{"name":"Craig Underhill","is_ca":false},{"name":"Desmond Yip","is_ca":false},{"name":"John Zalcberg","is_ca":false},{"name":"Dongsheng Tu","is_ca":false},{"name":"Rachel Goodwin","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04018596104969974,"gpt":0.3208746865091295,"spread":0.2806887254594298,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003209506,0.0001265992,0.0002401627,0.0002269624,0.0001748208,0.0003094468,0.000159909,0.0003130316,0.002749718],"category_scores_gemma":[0.001305235,0.00006715037,0.0004086636,0.0002963213,0.0001554799,0.0002026878,0.0002361788,0.0003782977,0.0001597898],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002264231,"about_ca_system_score_gemma":0.0003488928,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004414818,"about_ca_topic_score_gemma":0.01011258,"domain_scores_codex":[0.9998621,0.00004492304,0.00001368905,0.00001640648,0.00002164127,0.00004118248],"domain_scores_gemma":[0.9992383,0.0002608828,0.0002012984,0.00003348535,0.00003975695,0.0002262654],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.008516467,0.0001206058,0.9722903,0.00008651976,0.0002317616,0.0003355473,0.00004025442,0.000472529,0.001942811,0.00007010307,0.0007660056,0.01512709],"study_design_scores_gemma":[0.000102251,0.0005836309,0.996463,0.00003616474,0.0003142123,0.0004324373,0.0001047937,0.0008561573,0.0002632728,0.00006882328,0.0007682687,0.000007073365],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968334,0.001846152,0.00004884182,0.0001570981,0.0000194141,0.000004286592,0.0001943704,0.000003496023,0.0008929899],"genre_scores_gemma":[0.999136,0.0002488233,0.00005082222,0.00003072773,0.00002184253,0.000002284836,0.0002488485,0.000001515835,0.0002591215],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004414818,"threshold_uncertainty_score":0.009198725,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2126251787","doi":"10.1200/jco.2011.38.7571","title":"Progression-Free Survival: Meaningful or Simply Measurable?","year":2012,"lang":"en","type":"editorial","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":320,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Progression-free survival; Oncology; Randomized controlled trial; Internal medicine; Clinical endpoint; Standard of care; Overall survival; Tumor progression; Intensive care medicine; Cancer","authors":[{"name":"Christopher M. Booth","is_ca":true},{"name":"Elizabeth A. Eisenhauer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1833612787865125,"gpt":0.5217916929448325,"spread":0.33843041415832,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02304179,0.003639141,0.007301454,0.002474732,0.002617459,0.007658693,0.004301507,0.01698287,0.004378325],"category_scores_gemma":[0.09290659,0.001224454,0.002330665,0.002147875,0.005886909,0.007118287,0.00128325,0.03522267,0.004094829],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003425571,"about_ca_system_score_gemma":0.003089965,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001551133,"about_ca_topic_score_gemma":0.002847344,"domain_scores_codex":[0.987843,0.004714187,0.002581227,0.001103713,0.003430636,0.0003272948],"domain_scores_gemma":[0.9036091,0.07293212,0.003543217,0.00193487,0.01495597,0.003024783],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009860081,0.00001625895,0.0000480574,0.0009702166,0.00005021333,0.0001029281,0.00003550231,0.00002835022,0.00005327344,0.001092221,0.9808089,0.01669556],"study_design_scores_gemma":[0.0002089773,0.0001250863,0.0007067445,0.003284504,0.0002794693,0.0005817513,0.0001202914,0.0003679245,0.0002042975,0.005819366,0.9882433,0.00005835775],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.00004622786,0.03498119,0.0002521438,0.09669454,0.8670503,0.000023645,0.0000517966,0.00003990083,0.0008601588],"genre_scores_gemma":[0.0005880796,0.01905274,0.0002860675,0.04226843,0.9357775,0.00003097616,0.0000219065,0.00002518029,0.001949082],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.02304179,"threshold_uncertainty_score":0.1218581,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2770347143","doi":"10.1158/1078-0432.ccr-17-2484","title":"Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":318,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Royal College of Physicians and Surgeons of Canada; Conquer Cancer Foundation","keywords":"KRAS; Splenic flexure; Colorectal cancer; Medicine; Mutation; GNAS complex locus; Internal medicine; Cancer; Rectum; Oncology; Cancer research; Gastroenterology; Biology; Genetics; Gene; Colonoscopy","authors":[{"name":"Jonathan M. Loree","is_ca":false},{"name":"Allan Andresson Lima Pereira","is_ca":false},{"name":"Michael Lam","is_ca":false},{"name":"Alexandra N. Willauer","is_ca":false},{"name":"Kanwal Raghav","is_ca":false},{"name":"Arvind Dasari","is_ca":false},{"name":"Van K. Morris","is_ca":false},{"name":"Shailesh Advani","is_ca":false},{"name":"David G. Menter","is_ca":false},{"name":"Cathy Eng","is_ca":false},{"name":"Kenna Shaw","is_ca":false},{"name":"Russell R. Broaddus","is_ca":false},{"name":"Mark J. Routbort","is_ca":false},{"name":"Yusha Liu","is_ca":false},{"name":"Jeffrey S. Morris","is_ca":false},{"name":"Rajyalakshmi Luthra","is_ca":false},{"name":"Funda Meric‐Bernstam","is_ca":false},{"name":"Michael J. Overman","is_ca":false},{"name":"Dipen M. Maru","is_ca":false},{"name":"Scott Kopetz","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1301473757666578,"gpt":0.4891342404451145,"spread":0.3589868646784567,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001134003,0.0002180172,0.0004663684,0.0006691499,0.0002049922,0.0004961728,0.0002839878,0.0002771367,0.001309482],"category_scores_gemma":[0.003281691,0.0001325011,0.0003264912,0.0005200625,0.0002802211,0.0003910675,0.0006092306,0.0002859037,0.0003239562],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001667059,"about_ca_system_score_gemma":0.0001763998,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007524811,"about_ca_topic_score_gemma":0.001677749,"domain_scores_codex":[0.9990407,0.000281093,0.0001270019,0.0002809268,0.0001789242,0.00009143],"domain_scores_gemma":[0.9971765,0.0008881148,0.0009864912,0.0003950105,0.0002695891,0.0002842447],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005861699,0.0000175296,0.9909455,0.00001873959,0.00005123698,0.00007035826,0.00005599877,0.00009351004,0.002205727,0.00002962698,0.00007068984,0.005854936],"study_design_scores_gemma":[0.00002137769,0.0002353411,0.9968994,0.00001409025,0.00003251065,0.0008228039,0.0002235024,0.0008602422,0.0005304445,0.0002237857,0.0001309832,0.000005542083],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9993542,0.0001498957,0.0001897034,0.00002623124,0.000002521191,0.000003366431,0.00009306932,0.000003025851,0.000178004],"genre_scores_gemma":[0.9995105,0.00003468691,0.0002200778,0.00001669184,0.000004813993,0.00000244318,0.0001748863,0.00000205385,0.00003381088],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001309482,"threshold_uncertainty_score":0.0059973,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2152511454","doi":"10.1093/annonc/mdg500","title":"Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"F. Hoffmann-La Roche","keywords":"Capecitabine; Medicine; Internal medicine; Neutropenia; Fluorouracil; Stomatitis; Nausea; Regimen; Gastroenterology; Colorectal cancer; Adjuvant therapy; Surgery; Cancer; Oncology; Chemotherapy","authors":[{"name":"Werner Scheithauer","is_ca":false},{"name":"J McKendrick","is_ca":false},{"name":"S. Begbie","is_ca":false},{"name":"Markus Borner","is_ca":false},{"name":"W. Ivon Burns","is_ca":false},{"name":"Howard A. Burris","is_ca":false},{"name":"Jim Cassidy","is_ca":false},{"name":"Duncan I. Jodrell","is_ca":false},{"name":"P. Koralewski","is_ca":false},{"name":"E.L. Levine","is_ca":false},{"name":"Norbert Marschner","is_ca":false},{"name":"Jean A. Maroun","is_ca":true},{"name":"Pilar García‐Alfonso","is_ca":false},{"name":"Jerzy Tujakowski","is_ca":false},{"name":"Guy van Hazel","is_ca":false},{"name":"A. Wong","is_ca":false},{"name":"J. Załuski","is_ca":false},{"name":"Chris Twelves","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09975016200087691,"gpt":0.454884961949826,"spread":0.3551347999489491,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001652121,0.001703708,0.0033753,0.0005174465,0.0004191348,0.001088948,0.0009478425,0.001957767,0.003022402],"category_scores_gemma":[0.002306944,0.0006497796,0.002008097,0.0006779882,0.001489019,0.001051573,0.000271951,0.003647907,0.0005617138],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001016644,"about_ca_system_score_gemma":0.001201089,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001268088,"about_ca_topic_score_gemma":0.002346846,"domain_scores_codex":[0.9993082,0.00037283,0.00003829524,0.0001255775,0.00005576242,0.00009938679],"domain_scores_gemma":[0.9987003,0.000517467,0.0002933129,0.0001100103,0.00005315297,0.0003257493],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9676101,0.003215772,0.000474886,0.0005890593,0.0008875008,0.00006819188,0.00005795218,0.000470254,0.003271042,0.0001200644,0.0005054956,0.02272968],"study_design_scores_gemma":[0.9285459,0.06818707,0.000951385,0.00003667169,0.0006336747,0.0000582043,0.0000178154,0.0004327974,0.0007003121,0.00009680306,0.0003257428,0.00001356321],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9864122,0.00813977,0.0009060919,0.0007115888,0.0004425411,0.001142476,0.0006139569,0.00009111951,0.001540293],"genre_scores_gemma":[0.991385,0.0038065,0.0009757905,0.0006039584,0.0003036147,0.0008360212,0.0006023809,0.00002505519,0.001461662],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0033753,"threshold_uncertainty_score":0.01011091,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2158475201","doi":"10.1093/annonc/mdm492","title":"EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Hospital Foundation","funders":"Cancer Center, University of Colorado; Università degli Studi di Napoli Federico II","keywords":"Cetuximab; Medicine; Colorectal cancer; Internal medicine; Oncology; Epidermal growth factor receptor; Fluorescence in situ hybridization; Lung cancer; KRAS; Confidence interval; Cancer; Chemotherapy; Gene; Biology","authors":[{"name":"Federico Cappuzzo","is_ca":false},{"name":"Giovanna Finocchiaro","is_ca":false},{"name":"Elisa Rossi","is_ca":false},{"name":"Pasi A. Jänne","is_ca":false},{"name":"Carlo Carnaghi","is_ca":false},{"name":"C. Calandri","is_ca":true},{"name":"Katia Bencardino","is_ca":false},{"name":"C. Ligorio","is_ca":false},{"name":"Fortunato Ciardiello","is_ca":false},{"name":"Tiziana Pressiani","is_ca":false},{"name":"Annarita Destro","is_ca":false},{"name":"Massimo Roncalli","is_ca":false},{"name":"Lucio Crinò","is_ca":false},{"name":"Wilbur A. Franklin","is_ca":false},{"name":"Armando Santoro","is_ca":false},{"name":"Marileila Varella‐Garcia","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04960752627918864,"gpt":0.403707058447591,"spread":0.3540995321684024,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003739676,0.0002573554,0.0003484092,0.0005065961,0.0002479529,0.0003845629,0.000204798,0.0005722457,0.00169439],"category_scores_gemma":[0.001975809,0.0001580204,0.0003204907,0.0002883523,0.0002461791,0.0003383699,0.0001451172,0.0004954809,0.0002613296],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003792117,"about_ca_system_score_gemma":0.000204015,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002141946,"about_ca_topic_score_gemma":0.003421285,"domain_scores_codex":[0.9998403,0.00004330449,0.00001802992,0.00002771416,0.00002974694,0.0000408804],"domain_scores_gemma":[0.999042,0.0004377177,0.0002045655,0.00004595844,0.00008740296,0.0001823344],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001654416,0.0001018876,0.9897931,0.000009521582,0.00005113871,0.0002104223,0.00004171874,0.0002340067,0.00335712,0.00002052547,0.0002429468,0.00428317],"study_design_scores_gemma":[0.00004743094,0.0007309545,0.9959097,0.000004603102,0.00008254584,0.0006927148,0.00009336077,0.001115279,0.0009464307,0.00004786462,0.0003230657,0.000006073152],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9990096,0.0001682179,0.00003265861,0.00009299864,0.000008748932,0.000005088608,0.0000659092,0.000003752476,0.0006129967],"genre_scores_gemma":[0.9993875,0.00005443595,0.00003964218,0.00005175505,0.000009415214,0.000003823608,0.0001478072,0.000001324073,0.0003043168],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002141946,"threshold_uncertainty_score":0.005668283,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2121313610","doi":"10.1200/jco.2007.15.2090","title":"Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research","keywords":"Tolerability; Medicine; Oncology; Pharmacology; Internal medicine; Adverse effect","authors":[{"name":"Daniel G. Haller","is_ca":true},{"name":"Jim Cassidy","is_ca":true},{"name":"Stephen Clarke","is_ca":true},{"name":"David Cunningham","is_ca":true},{"name":"Eric Van Cutsem","is_ca":true},{"name":"Paulo M. Hoff","is_ca":true},{"name":"Mace L. Rothenberg","is_ca":true},{"name":"Leonard B. Saltz","is_ca":true},{"name":"Hans‐Joachim Schmoll","is_ca":true},{"name":"Carmen J. Allegra","is_ca":true},{"name":"Joseph R. Bertino","is_ca":true},{"name":"Jean-Yves Douillard","is_ca":true},{"name":"Bengt Gustavsson","is_ca":true},{"name":"G. Milano","is_ca":true},{"name":"Michael J. O’Connell","is_ca":true},{"name":"Youcef M. Rustum","is_ca":true},{"name":"Josep Tabernero","is_ca":true},{"name":"Frank Gilberg","is_ca":true},{"name":"Florin Sirzén","is_ca":true},{"name":"Chris Twelves","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2520781100918678,"gpt":0.4719691598207691,"spread":0.2198910497289013,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01611779,0.0002430625,0.0007125292,0.0009395508,0.000159464,0.0006645753,0.0003929533,0.0002494248,0.001353992],"category_scores_gemma":[0.02277555,0.0001786121,0.001755417,0.001183581,0.0005108314,0.0004344168,0.0004096098,0.0003387358,0.00024109],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000396155,"about_ca_system_score_gemma":0.0003052622,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004858231,"about_ca_topic_score_gemma":0.0005619315,"domain_scores_codex":[0.9908704,0.004700712,0.001667051,0.001508082,0.001048946,0.0002048122],"domain_scores_gemma":[0.9462717,0.02045136,0.02533513,0.005130757,0.002336707,0.0004743452],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005551725,0.00007431398,0.9523015,0.0006538667,0.003624926,0.0004805046,0.0003444573,0.001536306,0.007091371,0.0004263854,0.0003055885,0.0276091],"study_design_scores_gemma":[0.0001547682,0.001534935,0.9881534,0.00007572916,0.001674569,0.001994782,0.0001079226,0.0007633406,0.00294351,0.0003196235,0.002253862,0.00002362322],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9695031,0.01824624,0.006981832,0.0002314432,0.00003450677,0.0002081001,0.002091956,0.00004273005,0.002660051],"genre_scores_gemma":[0.9980428,0.0003898606,0.0007407122,0.00008619014,0.00003002678,0.00004567377,0.0005872486,0.00001548037,0.00006197354],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01611779,"threshold_uncertainty_score":0.08524007,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1844854109","doi":"10.1002/cncr.27935","title":"Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer","year":2012,"lang":"en","type":"article","venue":"Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Medicine; Medicaid; Cancer; Colorectal cancer; Internal medicine; Cohort; Relative survival; Population; Stage (stratigraphy); Multivariate analysis; Disease; Oncology; Cohort study; Cancer registry; Health care; Environmental health","authors":[{"name":"Genevieve M. Boland","is_ca":false},{"name":"George J. Chang","is_ca":false},{"name":"Alex B. Haynes","is_ca":false},{"name":"Yi‐Ju Chiang","is_ca":false},{"name":"Ryaz Chagpar","is_ca":true},{"name":"Yan Xing","is_ca":false},{"name":"Chung‐Yuan Hu","is_ca":false},{"name":"Barry W. Feig","is_ca":false},{"name":"Y. Nancy You","is_ca":false},{"name":"Janice N. Cormier","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07394323950985555,"gpt":0.3663922648586683,"spread":0.2924490253488128,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007425899,0.0001543219,0.0002402579,0.0003826823,0.0002543241,0.0003584109,0.0002113658,0.0003705526,0.0009838546],"category_scores_gemma":[0.004356771,0.00008924707,0.0003177041,0.0005855505,0.000200193,0.000297042,0.0002680746,0.0007780211,0.00006725508],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002755036,"about_ca_system_score_gemma":0.000415356,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004055755,"about_ca_topic_score_gemma":0.00719467,"domain_scores_codex":[0.9994336,0.0001981751,0.00006653676,0.00007425359,0.0001331898,0.00009423218],"domain_scores_gemma":[0.9964929,0.0008766314,0.001828252,0.0001167044,0.0002804291,0.0004050691],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00006234684,0.00002673583,0.9988085,0.000004409366,0.00003609115,0.00001084885,0.00001124241,0.0000327753,0.00002625219,0.000004219747,0.00004379742,0.00093283],"study_design_scores_gemma":[0.000006325648,0.00007026681,0.9995267,0.000003775661,0.00002358236,0.00005959959,0.00003614422,0.0001799748,0.00001450128,0.00001177193,0.00006591721,0.000001399722],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9988891,0.0003763695,0.00005828345,0.000149185,0.00000867515,0.000006046097,0.0001347237,0.000002477095,0.0003751171],"genre_scores_gemma":[0.9995784,0.00008455171,0.00005027086,0.00003715281,0.00001245367,0.000005061311,0.0001777189,6.669627e-7,0.000053693],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004055755,"threshold_uncertainty_score":0.00806433,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384520841","doi":"10.1200/jco.22.02760","title":"Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Bevacizumab; Medicine; Oxaliplatin; FOLFOX; Folinic acid; Internal medicine; Colorectal cancer; Oncology; Clinical endpoint; Chemotherapy; Placebo; Capecitabine; Hazard ratio; Progression-free survival; Surgery; Randomized controlled trial; Cancer; Confidence interval; Pathology","authors":[{"name":"Leonard B. Saltz","is_ca":true},{"name":"Stephen Clarke","is_ca":true},{"name":"Eduardo Díaz‐Rubio","is_ca":true},{"name":"Werner Scheithauer","is_ca":true},{"name":"Arié Figer","is_ca":true},{"name":"Ralph Wong","is_ca":true},{"name":"Sheryl Koski","is_ca":true},{"name":"Mikhail Lichinitser","is_ca":true},{"name":"Tsai‐Shen Yang","is_ca":true},{"name":"Fernando Rivera","is_ca":true},{"name":"Félix Couture","is_ca":true},{"name":"Florin Sirzén","is_ca":true},{"name":"Jim Cassidy","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1009913211866394,"gpt":0.4850312222814466,"spread":0.3840399010948072,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002385921,0.001396155,0.003552983,0.0005452862,0.0003710026,0.00121681,0.0009522244,0.001612481,0.003263533],"category_scores_gemma":[0.001804532,0.0007422256,0.001498511,0.0006413559,0.001052817,0.0007638482,0.0003721075,0.002236001,0.0006342672],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001078153,"about_ca_system_score_gemma":0.001596642,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000924804,"about_ca_topic_score_gemma":0.002890087,"domain_scores_codex":[0.9989074,0.0006687189,0.00005372516,0.0001411272,0.0001040093,0.0001250654],"domain_scores_gemma":[0.9990008,0.0002104952,0.0002597339,0.00006929014,0.00007153801,0.000388063],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9325966,0.02174859,0.001129427,0.0009312095,0.001478687,0.00008433691,0.00004715997,0.0006222131,0.007183388,0.0001002959,0.0009981145,0.03308003],"study_design_scores_gemma":[0.8866789,0.1102995,0.001156179,0.00003173367,0.0004043467,0.00003953736,0.00000805206,0.0004112721,0.0003432598,0.00005773824,0.0005599892,0.000009657406],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9798666,0.009489913,0.001126071,0.0007757593,0.0006614347,0.005690438,0.0007009408,0.0001417214,0.001546998],"genre_scores_gemma":[0.978735,0.006542414,0.002748481,0.001322731,0.0008459035,0.006767683,0.00102855,0.00003471546,0.001974589],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003552983,"threshold_uncertainty_score":0.01261806,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2120713475","doi":"10.1200/jco.2006.08.6652","title":"Neurotoxicity From Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: NSABP C-07","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":240,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Michael Smith Health Research BC; Ministerul Cercetării, Inovării şi Digitalizării; U.S. Department of Health and Human Services","keywords":"Oxaliplatin; Medicine; Neurotoxicity; Bolus (digestion); Adverse effect; Chemotherapy; Gastroenterology; Internal medicine; Surgery; Fluorouracil; Colorectal cancer; Toxicity; Anesthesia; Cancer","authors":[{"name":"Stephanie R. Land","is_ca":false},{"name":"Jacek A Kopec","is_ca":false},{"name":"Reena S. Cecchini","is_ca":false},{"name":"Patricia A. Ganz","is_ca":false},{"name":"H. Samuel Wieand","is_ca":false},{"name":"Linda H. Colangelo","is_ca":false},{"name":"Kate Murphy","is_ca":false},{"name":"J. Philip Kuebler","is_ca":false},{"name":"Thomas E. Seay","is_ca":false},{"name":"Burton Needles","is_ca":false},{"name":"James D. Bearden","is_ca":false},{"name":"Lauren K. Colman","is_ca":false},{"name":"Keith S. Lanier","is_ca":false},{"name":"Eduardo R. Pajon","is_ca":false},{"name":"David Cella","is_ca":false},{"name":"Roy E. Smith","is_ca":false},{"name":"Michael J. O’Connell","is_ca":false},{"name":"Joseph P. Costantino","is_ca":false},{"name":"Norman Wolmark","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07383472491052075,"gpt":0.4402460097146234,"spread":0.3664112848041026,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002065154,0.0004729259,0.0008675234,0.0003757508,0.0003494034,0.0004603136,0.0006371991,0.0005418104,0.001051957],"category_scores_gemma":[0.001246366,0.0002537651,0.0009033215,0.0003727338,0.0004720642,0.0002628832,0.0003305493,0.001055282,0.0001296925],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001302701,"about_ca_system_score_gemma":0.003313986,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002352598,"about_ca_topic_score_gemma":0.009571764,"domain_scores_codex":[0.9990634,0.0006558027,0.00005179504,0.00005185228,0.00009642484,0.00008069377],"domain_scores_gemma":[0.9990773,0.0002666748,0.0002610596,0.00004564034,0.00006507707,0.0002842837],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7075316,0.0396421,0.07182992,0.001448354,0.002566103,0.0003020867,0.0002400261,0.003588588,0.02671794,0.0002187571,0.003571215,0.1423433],"study_design_scores_gemma":[0.3136063,0.5879684,0.08547226,0.000140551,0.001403153,0.0005566833,0.00009272844,0.002100922,0.006487559,0.0001092272,0.002038235,0.00002398679],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9981154,0.0006734066,0.00007991199,0.00008426089,0.00001400798,0.0006255676,0.0001319174,0.000006953055,0.0002684934],"genre_scores_gemma":[0.995438,0.001014129,0.0008672809,0.0003504396,0.00005424276,0.001181958,0.0007089522,0.000005443343,0.0003795021],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002352598,"threshold_uncertainty_score":0.01092172,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4200445204","doi":"10.3390/curroncol28060447","title":"Pathological Features and Prognostication in Colorectal Cancer","year":2021,"lang":"en","type":"review","venue":"Current Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":239,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false},"ca_institutions":"","funders":"","keywords":"Medicine; Perineural invasion; Colorectal cancer; KRAS; Pathological; Tumor budding; Lymph node; Oncology; Pathological staging; Stage (stratigraphy); Cancer; Adjuvant therapy; Disease; Microsatellite instability; Internal medicine; Pathology; Metastasis; Lymph node metastasis","authors":[{"name":"Kabytto Chen","is_ca":false},{"name":"Geoffrey Collins","is_ca":false},{"name":"Henry Wang","is_ca":false},{"name":"James Wei Tatt Toh","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2063818137940601,"gpt":0.503537325562874,"spread":0.2971555117688139,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006262971,0.0004963812,0.0009337345,0.002363213,0.0001628448,0.000779079,0.0004720832,0.0005037279,0.002434413],"category_scores_gemma":[0.001903661,0.0001838221,0.0008181499,0.002288299,0.0003568493,0.0007418137,0.0003887541,0.0007186233,0.0005931974],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004277703,"about_ca_system_score_gemma":0.001019998,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001562152,"about_ca_topic_score_gemma":0.002960938,"domain_scores_codex":[0.9996797,0.00008214924,0.00007515655,0.00004399716,0.00009980505,0.00001926513],"domain_scores_gemma":[0.9993074,0.0004219128,0.0001225047,0.00001214473,0.0001198479,0.00001627458],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001305575,0.00003406539,0.001599928,0.0491003,0.0003322095,0.0001827964,0.00007527044,0.0002711803,0.0005832419,0.001146071,0.01362202,0.9329224],"study_design_scores_gemma":[0.00003808257,0.0002951533,0.01442994,0.05016453,0.001813758,0.004385354,0.0002039248,0.0002420226,0.0008111821,0.002960462,0.9246017,0.00005387858],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001656917,0.9992102,0.00004793092,0.0001568602,0.00006356977,0.000002918089,0.00002336519,0.000002231859,0.0003272102],"genre_scores_gemma":[0.001358717,0.9982005,0.0001045497,0.00008457078,0.0000668603,0.000003123086,0.00003698191,7.092483e-7,0.0001439363],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002434413,"threshold_uncertainty_score":0.008143902,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2161664263","doi":"10.1200/jco.2006.08.1935","title":"Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":238,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Surrogate endpoint; Internal medicine; Hazard ratio; Colorectal cancer; Oncology; Randomized controlled trial; Progression-free survival; Proportional hazards model; Clinical endpoint; Population; Chemotherapy; Cancer; Confidence interval; Surgery","authors":[{"name":"Patricia A. Tang","is_ca":true},{"name":"Søren M. Bentzen","is_ca":true},{"name":"Eric X. Chen","is_ca":true},{"name":"Lillian L. Siu","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2130243668631893,"gpt":0.5334961922847858,"spread":0.3204718254215966,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.06386794,0.001418009,0.008317772,0.003947735,0.0004019612,0.003097527,0.001206359,0.001781924,0.00246924],"category_scores_gemma":[0.1458237,0.0006845398,0.01259392,0.004234335,0.001164942,0.001331029,0.001040378,0.001803824,0.0002853794],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002030887,"about_ca_system_score_gemma":0.003032955,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006855593,"about_ca_topic_score_gemma":0.00134934,"domain_scores_codex":[0.9296074,0.04957183,0.01302728,0.002594643,0.00461075,0.0005880445],"domain_scores_gemma":[0.7922987,0.1500848,0.04718865,0.004043409,0.005220917,0.001163562],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"systematic_review","study_design_scores_codex":[0.271906,0.001134333,0.06243701,0.1521856,0.3716356,0.0006484193,0.0002864098,0.007385806,0.001869281,0.00108696,0.002076009,0.1273487],"study_design_scores_gemma":[0.2770704,0.03809893,0.1349309,0.03781573,0.4899385,0.001515861,0.0003153436,0.006136438,0.002226832,0.00302566,0.008620771,0.0003045725],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.2586702,0.7292644,0.004354154,0.001068653,0.0003062541,0.003106484,0.002264774,0.00008377873,0.0008813681],"genre_scores_gemma":[0.8828933,0.1014121,0.006349878,0.001651395,0.0003325477,0.004378907,0.002770409,0.00002984239,0.0001815202],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.998582,"threshold_uncertainty_score":0.33777,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2598954950","doi":"10.1158/2159-8290.cd-16-0795","title":"A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i> -Mutant Colorectal Cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Seventh Framework Programme; Deutschen Konsortium für Translationale Krebsforschung","keywords":"Cetuximab; Medicine; Colorectal cancer; Tolerability; Oncology; Internal medicine; Concomitant; Cancer; Population; Pharmacology; Adverse effect","authors":[{"name":"Robin M.J.M. van Geel","is_ca":false},{"name":"Josep Tabernero","is_ca":false},{"name":"Elena Élez","is_ca":false},{"name":"Johanna C. Bendell","is_ca":false},{"name":"Anna Spreafico","is_ca":true},{"name":"Martin Schüler","is_ca":false},{"name":"Takayuki Yoshino","is_ca":false},{"name":"Jean‐Pierre Delord","is_ca":false},{"name":"Yasuhide Yamada","is_ca":false},{"name":"Martijn P. Lolkema","is_ca":false},{"name":"Jason E. Faris","is_ca":false},{"name":"Ferry A.L.M. Eskens","is_ca":false},{"name":"Sunil Sharma","is_ca":false},{"name":"Rona Yaeger","is_ca":false},{"name":"Heinz‐Josef Lenz","is_ca":false},{"name":"Zev A. Wainberg","is_ca":false},{"name":"Emin Avşar","is_ca":false},{"name":"Arkendu Chatterjee","is_ca":false},{"name":"Savina Jaeger","is_ca":false},{"name":"Eugene Tan","is_ca":false},{"name":"Kati Maharry","is_ca":false},{"name":"Tim Demuth","is_ca":false},{"name":"Jan H.M. Schellens","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04112415896288415,"gpt":0.3710117573194283,"spread":0.3298875983565441,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009313439,0.001124903,0.001630252,0.0004172871,0.0003883785,0.0007964521,0.0007678958,0.0009428512,0.001969518],"category_scores_gemma":[0.0004504828,0.0005564966,0.0008802552,0.0003575099,0.0007091158,0.0006672785,0.0002826529,0.003071203,0.0004724883],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000892434,"about_ca_system_score_gemma":0.001143115,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001110152,"about_ca_topic_score_gemma":0.002859778,"domain_scores_codex":[0.9996238,0.0001270839,0.00002481269,0.00007856903,0.00004867105,0.00009712089],"domain_scores_gemma":[0.9995759,0.00004155367,0.00008653932,0.00005551467,0.00003144033,0.00020903],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5010539,0.1343141,0.004329945,0.0006527545,0.00126677,0.0002223643,0.0003067222,0.003658797,0.2700046,0.0003887422,0.002209011,0.08159226],"study_design_scores_gemma":[0.25775,0.6955452,0.01004699,0.00002584518,0.0004884751,0.0003825408,0.00007487051,0.002016178,0.0308321,0.0001660737,0.0026274,0.00004439135],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975241,0.0005020376,0.0003392129,0.0001170881,0.00005608466,0.0006545307,0.0002119969,0.00005041378,0.0005445179],"genre_scores_gemma":[0.9955314,0.0004872103,0.001162146,0.0001929054,0.00005235874,0.0007034534,0.0005991918,0.00001464982,0.001256832],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001969518,"threshold_uncertainty_score":0.006588697,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2108585052","doi":"10.1200/jco.2006.06.1440","title":"Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Oxaliplatin; Medicine; Fluorouracil; Colorectal cancer; Internal medicine; Oncology; Chemotherapy; Phases of clinical research; Cancer","authors":[{"name":"Sylvie Giacchetti","is_ca":true},{"name":"Georg A. Bjarnason","is_ca":true},{"name":"Carlo Garufi","is_ca":true},{"name":"Dominique Genet","is_ca":true},{"name":"Stefano Iacobelli","is_ca":true},{"name":"Marco Tampellini","is_ca":true},{"name":"Rune Smaaland","is_ca":true},{"name":"C. Focan","is_ca":true},{"name":"Bruno Coudert","is_ca":true},{"name":"Yves Humblet","is_ca":true},{"name":"Jean Luc Canon","is_ca":true},{"name":"Antoine Adenis","is_ca":true},{"name":"Giovanni Lo Re","is_ca":true},{"name":"Carlos Carvalho","is_ca":true},{"name":"Johannes Schueller","is_ca":true},{"name":"Nicole Anciaux","is_ca":true},{"name":"M.A. Lentz","is_ca":true},{"name":"Benoît Baron","is_ca":true},{"name":"Thierry Gorlia","is_ca":true},{"name":"Françis Lévi","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2516237123749373,"gpt":0.5059338816823887,"spread":0.2543101693074514,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002606837,0.001057255,0.001761284,0.0003365756,0.0003047728,0.0007079054,0.0007805902,0.001261849,0.004008541],"category_scores_gemma":[0.001827447,0.0003773005,0.001763222,0.0003217164,0.0007763059,0.0005198803,0.0003439609,0.001658586,0.0003904036],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008449045,"about_ca_system_score_gemma":0.001366696,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000681547,"about_ca_topic_score_gemma":0.001162582,"domain_scores_codex":[0.9991511,0.0005873982,0.00003507878,0.0001080117,0.00003949682,0.00007883841],"domain_scores_gemma":[0.9987695,0.0003946666,0.0003735221,0.0001003124,0.00005346128,0.0003085499],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9784234,0.006615679,0.0008435682,0.0002208832,0.0006463234,0.00002076447,0.00002528843,0.0005542138,0.002360036,0.00007798632,0.0003392526,0.009872592],"study_design_scores_gemma":[0.8871003,0.1093022,0.001930331,0.00001652148,0.0003075002,0.00002186895,0.000007690882,0.0004476778,0.0004913305,0.00006297126,0.0003040931,0.00000749825],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943643,0.001703662,0.0005158764,0.0003112636,0.0002708742,0.001771066,0.0003505864,0.00003879821,0.0006735509],"genre_scores_gemma":[0.9905437,0.00100975,0.0020265,0.0007045611,0.0003277648,0.003184527,0.000791713,0.00001610456,0.001395335],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004008541,"threshold_uncertainty_score":0.01378644,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2027176779","doi":"10.1038/bjc.2011.201","title":"XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results","year":2011,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CancerCare Manitoba; St. Boniface Hospital","funders":"","keywords":"Folinic acid; Oxaliplatin; Medicine; Bevacizumab; Capecitabine; Internal medicine; FOLFOX; Colorectal cancer; Population; Placebo; Hazard ratio; Fluorouracil; Oncology; Neutropenia; Gastroenterology; Surgery; Chemotherapy; Cancer; Confidence interval; Pathology","authors":[{"name":"J Cassidy","is_ca":false},{"name":"Stephen Clarke","is_ca":false},{"name":"Eduardo Díaz‐Rubio","is_ca":false},{"name":"Werner Scheithauer","is_ca":false},{"name":"Arié Figer","is_ca":false},{"name":"Ralph Wong","is_ca":true},{"name":"Sheryl Koski","is_ca":false},{"name":"Karen Rittweger","is_ca":false},{"name":"Frank Gilberg","is_ca":false},{"name":"Leonard B. Saltz","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04379543442494756,"gpt":0.3317247483501661,"spread":0.2879293139252185,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01263767,0.001238476,0.003922404,0.002195299,0.0003267892,0.00300473,0.001315903,0.00113806,0.01204902],"category_scores_gemma":[0.02453183,0.0006987173,0.00670453,0.003085217,0.0003684565,0.001583857,0.001417076,0.002648795,0.001929113],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001615524,"about_ca_system_score_gemma":0.002627996,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002568337,"about_ca_topic_score_gemma":0.005294082,"domain_scores_codex":[0.9919734,0.003682674,0.001388954,0.0005756797,0.001898783,0.0004805081],"domain_scores_gemma":[0.9805577,0.007540696,0.007364144,0.0007498425,0.002743948,0.001043691],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1167881,0.0007298752,0.007674604,0.08348391,0.0290276,0.0002198366,0.0002279684,0.001513877,0.002683219,0.001234129,0.06686598,0.6895508],"study_design_scores_gemma":[0.08573972,0.0376766,0.109087,0.05276265,0.132826,0.002005991,0.0003012136,0.0008375889,0.003682692,0.003446648,0.571193,0.0004409064],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.04095284,0.889412,0.001925014,0.006926526,0.00475826,0.001336827,0.03311338,0.0001751864,0.02139992],"genre_scores_gemma":[0.3154329,0.5561017,0.006146017,0.02162877,0.009201923,0.002814914,0.07556511,0.0004974271,0.0126112],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01263767,"threshold_uncertainty_score":0.06683522,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2135454464","doi":"10.1371/journal.pone.0047054","title":"The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis","year":2012,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"CIHR Skin Research Training Centre; Canadian Institutes of Health Research; Canadian Dermatology Foundation","keywords":"Colorectal cancer; Meta-analysis; Medicine; Oncology; Melanoma; Cancer; Mutation; Mutation testing; Value (mathematics); Internal medicine; Cancer research; Biology; Genetics; Statistics; Gene","authors":[{"name":"Gholamreza Safaee Ardekani","is_ca":true},{"name":"Seyed Mehdi Jafarnejad","is_ca":true},{"name":"Ardavan Saeedi","is_ca":true},{"name":"Gang Li","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1484729905950436,"gpt":0.3465267106802264,"spread":0.1980537200851828,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01389312,0.002565129,0.01461422,0.007835842,0.0006463351,0.002657967,0.002365987,0.002158711,0.002894637],"category_scores_gemma":[0.03331885,0.001460421,0.03772851,0.008494853,0.0006771671,0.001389265,0.001233317,0.001453621,0.0002429918],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002193812,"about_ca_system_score_gemma":0.002785545,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006740468,"about_ca_topic_score_gemma":0.01378544,"domain_scores_codex":[0.9896783,0.005406018,0.002392954,0.001173355,0.001023299,0.0003259983],"domain_scores_gemma":[0.9722879,0.02172372,0.003533321,0.0006633769,0.001469023,0.0003227311],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.00187156,0.00002076957,0.01427653,0.2117161,0.7619993,0.0002330766,0.00007279192,0.0008877115,0.0002530025,0.00009616253,0.0006121898,0.007960682],"study_design_scores_gemma":[0.000303791,0.0001290238,0.005814539,0.009612834,0.9827695,0.0001411783,0.00002984214,0.000271142,0.00009074398,0.0001092166,0.000708472,0.00001969832],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01041755,0.9875292,0.0006066229,0.0002472624,0.0001315162,0.0001674682,0.0006572345,0.00002594175,0.0002171769],"genre_scores_gemma":[0.3687291,0.6246638,0.003080486,0.0007020991,0.0003746408,0.000929604,0.001129777,0.00003665193,0.0003538479],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01461422,"threshold_uncertainty_score":0.07347471,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2068694673","doi":"10.2217/pgs.11.72","title":"Dihydropyrimidine Dehydrogenase Gene as a Major Predictor of Severe 5-Fluorouracil Toxicity","year":2011,"lang":"en","type":"review","venue":"Pharmacogenomics","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"","keywords":"Dihydropyrimidine dehydrogenase; Fluorouracil; Toxicity; Gene; Pharmacology; Chemistry; Cancer research; Medicine; Thymidylate synthase; Internal medicine; Biochemistry; Chemotherapy","authors":[{"name":"Ursula Amstutz","is_ca":true},{"name":"Tanja K. Froehlich","is_ca":false},{"name":"Carlo R. Largiadèr","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0719621557198927,"gpt":0.3538005639990978,"spread":0.2818384082792051,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006665524,0.0006420148,0.001858416,0.001591711,0.0001139963,0.0004806533,0.0005547905,0.0006684159,0.001758407],"category_scores_gemma":[0.001285823,0.000204575,0.0006007588,0.00186041,0.0002629586,0.0003826384,0.0002363667,0.0007588551,0.0006879747],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004001824,"about_ca_system_score_gemma":0.0008564057,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001812457,"about_ca_topic_score_gemma":0.002325063,"domain_scores_codex":[0.9997824,0.00005603383,0.00004045113,0.00004624099,0.00006200783,0.00001300351],"domain_scores_gemma":[0.9993867,0.000374833,0.00009606139,0.00000928875,0.0001114308,0.00002177695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002864742,0.00004766972,0.005287837,0.01522416,0.0005940896,0.0003980648,0.0000313629,0.0003169076,0.0008673887,0.0007449244,0.01148212,0.964719],"study_design_scores_gemma":[0.000244582,0.0007011172,0.08786121,0.02148184,0.005066554,0.01621702,0.0002329144,0.001166759,0.003258988,0.003343232,0.8602693,0.0001565884],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004030277,0.9989694,0.00008346127,0.0001899821,0.00004690776,0.000002213302,0.0000283513,0.000003504503,0.0002729903],"genre_scores_gemma":[0.002693955,0.9966865,0.0001852911,0.0000998453,0.00008367102,0.000004464415,0.00006159925,0.000001005004,0.0001835319],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001858416,"threshold_uncertainty_score":0.005882442,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1981284988","doi":"10.1016/j.ccr.2013.05.014","title":"A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention","year":2013,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Deutsche Forschungsgemeinschaft; Helmholtz-Gemeinschaft; Partenariat Canadien Contre Le Cancer; Wellcome Trust","keywords":"Carcinogenesis; Cancer research; Colorectal cancer; Biology; MAPK/ERK pathway; Tumor progression; Somatic cell; Mutation; Hyperplasia; Cancer; Signal transduction; Bioinformatics; Medicine; Gene; Genetics; Endocrinology","authors":[{"name":"Roland Rad","is_ca":false},{"name":"Juan Cadiñanos","is_ca":false},{"name":"Lena Rad","is_ca":false},{"name":"Ignacio Varela","is_ca":false},{"name":"Alexander Strong","is_ca":false},{"name":"Lydia Kriegl","is_ca":false},{"name":"Fernando Constantino‐Casas","is_ca":false},{"name":"Stefan Eser","is_ca":false},{"name":"Maren Hieber","is_ca":false},{"name":"Barbara Seidler","is_ca":false},{"name":"Stacey Price","is_ca":false},{"name":"Mario F. Fraga","is_ca":false},{"name":"Vincenzo Calvanese","is_ca":false},{"name":"Gary J. Hoffman","is_ca":false},{"name":"Hannes Ponstingl","is_ca":false},{"name":"Günter Schneider","is_ca":false},{"name":"Kosuke Yusa","is_ca":false},{"name":"Carolyn Grove","is_ca":false},{"name":"Roland M. Schmid","is_ca":false},{"name":"Wei Wang","is_ca":false},{"name":"George S. Vassiliou","is_ca":false},{"name":"Thomas Kirchner","is_ca":false},{"name":"Ultan McDermott","is_ca":false},{"name":"Pentao Liu","is_ca":false},{"name":"Dieter Saur","is_ca":false},{"name":"Allan Bradley","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0440716357610673,"gpt":0.3372972348395828,"spread":0.2932255990785155,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001133921,0.0003483469,0.0002438001,0.0004688203,0.0001578168,0.0001948272,0.0002300031,0.0003247716,0.001759948],"category_scores_gemma":[0.00006531392,0.000149403,0.0003103397,0.000132322,0.000271165,0.0001529343,0.0001710847,0.0007980411,0.0002509015],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003326848,"about_ca_system_score_gemma":0.0003298287,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008135906,"about_ca_topic_score_gemma":0.001301927,"domain_scores_codex":[0.9999288,0.0000115298,0.000004758179,0.00001501972,0.00002054441,0.00001929269],"domain_scores_gemma":[0.9999526,0.000005527532,0.00001196435,0.000006464553,0.000004082563,0.00001951501],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0003071427,0.0001410937,0.0001179922,0.0000314943,0.000003817079,0.000139816,0.0000115313,0.0002393636,0.9959623,0.0008199901,0.00007026259,0.002155207],"study_design_scores_gemma":[0.0003148492,0.005035338,0.003006658,0.00001919056,0.00004586424,0.001241565,0.00004175513,0.00685908,0.9746014,0.0009338464,0.007882963,0.00001733905],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839538,0.00107993,0.009589864,0.0003874662,0.00006491516,0.0001947123,0.00040656,0.000243674,0.004079038],"genre_scores_gemma":[0.9877038,0.001031102,0.006335057,0.00005770462,0.00001107147,0.0001110679,0.0003063476,0.00001866248,0.004425185],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001759948,"threshold_uncertainty_score":0.005887628,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2123811123","doi":"10.1093/annonc/mdn370","title":"Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"National Institute for Health and Care Research; Roche","keywords":"FOLFOX; Medicine; Oxaliplatin; Folinic acid; Internal medicine; Capecitabine; Irinotecan; Colorectal cancer; FOLFIRINOX; Neutropenia; Oncology; FOLFIRI; Population; Clinical endpoint; Fluorouracil; Surgery; Chemotherapy; Cancer; Randomized controlled trial","authors":[{"name":"Mace L. Rothenberg","is_ca":false},{"name":"John V. Cox","is_ca":false},{"name":"Charles Butts","is_ca":false},{"name":"Matilde Navarro","is_ca":false},{"name":"Y.-J. Bang","is_ca":false},{"name":"Rakesh Goel","is_ca":true},{"name":"Simon Gollins","is_ca":false},{"name":"Lillian L. Siu","is_ca":true},{"name":"Shelly Laguerre","is_ca":false},{"name":"David Cunningham","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1341549568313934,"gpt":0.4386820001262048,"spread":0.3045270432948114,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003167934,0.002333801,0.00418616,0.0007712488,0.0005605168,0.001346215,0.001498362,0.002165632,0.006534304],"category_scores_gemma":[0.00221641,0.001007431,0.002391268,0.0007621247,0.001725389,0.001667782,0.000514014,0.003959871,0.0009422245],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001329549,"about_ca_system_score_gemma":0.001525786,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001734664,"about_ca_topic_score_gemma":0.003777356,"domain_scores_codex":[0.9989015,0.0006337966,0.00005699558,0.0001771107,0.00006579555,0.0001646654],"domain_scores_gemma":[0.9983256,0.0005578581,0.0003445,0.000159091,0.00007323547,0.000539641],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9840266,0.005501032,0.0002381677,0.0002316854,0.0005776518,0.00001771049,0.00003128653,0.0002147244,0.001472822,0.0000477573,0.0002804281,0.007360236],"study_design_scores_gemma":[0.9381227,0.06004042,0.000672038,0.00001194824,0.0003981629,0.00001436089,0.00001099211,0.0001667344,0.0003157428,0.00004162116,0.0001979404,0.000007372645],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908075,0.003606124,0.0005625449,0.000570613,0.0005147719,0.001878722,0.0007440146,0.0001011361,0.001214724],"genre_scores_gemma":[0.9885076,0.002978269,0.001403048,0.0007531418,0.0005870581,0.001987434,0.0008328482,0.00003697151,0.002913598],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006534304,"threshold_uncertainty_score":0.02185947,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2138075845","doi":"10.1093/annonc/mdp533","title":"Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review","year":2009,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital; Cancer Care Ontario; McMaster University; London Health Sciences Centre","funders":"","keywords":"Bevacizumab; Medicine; Internal medicine; Colorectal cancer; Chemotherapy; Oncology; Hazard ratio; Irinotecan; Chemotherapy regimen; Adverse effect; Regimen; Cetuximab; Surgery; Gastrointestinal perforation; Cancer; Confidence interval","authors":[{"name":"Stephen Welch","is_ca":true},{"name":"Karen Spithoff","is_ca":true},{"name":"R. Bryan Rumble","is_ca":true},{"name":"Jean A. Maroun","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05019558973070794,"gpt":0.4076534941457312,"spread":0.3574579044150232,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002746267,0.0008342428,0.005898328,0.002074712,0.0002348065,0.0009452241,0.0009141197,0.001058705,0.004364737],"category_scores_gemma":[0.01151341,0.0006965147,0.006367563,0.002721447,0.0004941033,0.0008292099,0.0006382965,0.001250718,0.0001826268],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001963299,"about_ca_system_score_gemma":0.00257935,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006510327,"about_ca_topic_score_gemma":0.0301522,"domain_scores_codex":[0.9979796,0.0009705527,0.0005502687,0.0001874598,0.0002400541,0.00007212622],"domain_scores_gemma":[0.9940301,0.003736446,0.00174745,0.00007373194,0.0002694298,0.0001427485],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.005682032,0.0001011842,0.002277996,0.810684,0.08652505,0.0001745199,0.0001722296,0.0003977715,0.0005581955,0.0001955475,0.003024208,0.09020732],"study_design_scores_gemma":[0.01243049,0.004217223,0.01435045,0.2634904,0.6714915,0.0007115203,0.0002620184,0.0003698116,0.0006054449,0.000346727,0.03164303,0.00008140216],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003357627,0.9956357,0.00009452251,0.0001681623,0.0001214413,0.0001493527,0.0001906325,0.000007180686,0.0002754438],"genre_scores_gemma":[0.07090223,0.9270139,0.0006643743,0.0007165876,0.0001263576,0.0002179252,0.000144431,0.000006222129,0.0002079447],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.006510327,"threshold_uncertainty_score":0.01460147,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1831535185","doi":"","title":"Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"","keywords":"Methylenetetrahydrofolate reductase; Thymidylate synthase; Colorectal cancer; Internal medicine; Genotyping; Allele; Odds ratio; Genotype; Oncology; Medicine; Gastroenterology; Fluorouracil; Biology; Chemotherapy; Cancer; Genetics; Gene","authors":[{"name":"Victor Cohen","is_ca":true},{"name":"Valérie Panet-Raymond","is_ca":false},{"name":"Nelly Sabbaghian","is_ca":false},{"name":"Isabelle Morin","is_ca":false},{"name":"Gerald Batist","is_ca":false},{"name":"Rima Rozen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03817776695316645,"gpt":0.3224104275268397,"spread":0.2842326605736733,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002102793,0.0002114918,0.0002874016,0.0003011758,0.000217676,0.000180666,0.0001357945,0.0004758439,0.001364107],"category_scores_gemma":[0.0008613092,0.0001136247,0.0002179206,0.0003343424,0.0001830472,0.00009358879,0.0001183412,0.0003623247,0.0001772959],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001370506,"about_ca_system_score_gemma":0.0001649235,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001206066,"about_ca_topic_score_gemma":0.001233582,"domain_scores_codex":[0.9998558,0.00004602334,0.00001084676,0.00003427557,0.00002897423,0.00002414266],"domain_scores_gemma":[0.9994733,0.0001706631,0.0001579992,0.00001986506,0.00003316227,0.0001451011],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001025388,0.00007282555,0.9897791,0.00001792558,0.00007076289,0.0002477709,0.00003041524,0.00007905177,0.005394453,0.00001138398,0.00007829363,0.003192635],"study_design_scores_gemma":[0.00002973402,0.0004335056,0.9974559,0.000003180964,0.00004684259,0.001022009,0.00002918812,0.0003287869,0.0004020947,0.00001693532,0.0002292137,0.000002563563],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9994372,0.0003070683,0.00007020344,0.00003905082,0.00000454166,0.000002755093,0.00006931584,0.000002550691,0.00006732522],"genre_scores_gemma":[0.9996957,0.00005154218,0.0000746752,0.00001171527,0.00001016816,0.000002576603,0.00007761024,6.87441e-7,0.00007539034],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001364107,"threshold_uncertainty_score":0.004563391,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2006709656","doi":"10.1038/sj.bjc.6603055","title":"Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer","year":2006,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Erlotinib; Medicine; Rash; Internal medicine; Colorectal cancer; Cancer; Epidermal growth factor receptor; Adverse effect; Oncology; Gastroenterology; Progressive disease; Phases of clinical research; Chemotherapy","authors":[{"name":"Carol Townsley","is_ca":true},{"name":"Pierre Major","is_ca":true},{"name":"Lillian L. Siu","is_ca":true},{"name":"Janet Dancey","is_ca":false},{"name":"E Chen","is_ca":true},{"name":"Gregory R. Pond","is_ca":true},{"name":"Trudey Nicklee","is_ca":true},{"name":"Jcm Ho","is_ca":true},{"name":"David W. Hedley","is_ca":true},{"name":"Ming‐Sound Tsao","is_ca":true},{"name":"Malcolm J. Moore","is_ca":true},{"name":"Amit M. Oza","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01175758132970531,"gpt":0.3057892982061223,"spread":0.294031716876417,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001022297,0.001522636,0.002208264,0.0003906543,0.0003082173,0.0006198457,0.0005150749,0.0007614379,0.002185224],"category_scores_gemma":[0.0006259116,0.0005055083,0.0007531794,0.0003410327,0.0006459518,0.0004154617,0.0002558456,0.0014685,0.0005656543],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007545965,"about_ca_system_score_gemma":0.001283606,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001110643,"about_ca_topic_score_gemma":0.002501466,"domain_scores_codex":[0.9996879,0.0001437116,0.00001368087,0.00004305594,0.00003483765,0.00007689567],"domain_scores_gemma":[0.9996145,0.00005406851,0.00005916427,0.00002842322,0.00003119478,0.0002126696],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6186276,0.07345847,0.01827485,0.001247793,0.001431592,0.0009113355,0.0003381683,0.004135467,0.1079032,0.0003670446,0.004859308,0.1684453],"study_design_scores_gemma":[0.3582563,0.5991831,0.02723967,0.00002822975,0.0004518967,0.0006669263,0.00007042079,0.001781264,0.00785981,0.000121241,0.004304735,0.00003646365],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941317,0.00179967,0.0004621993,0.000218596,0.00007582409,0.001623679,0.0005803858,0.00005675708,0.001051201],"genre_scores_gemma":[0.9887299,0.002116914,0.001320767,0.0005057849,0.0001719741,0.002390129,0.002126368,0.00002032393,0.002617936],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002208264,"threshold_uncertainty_score":0.007310331,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2125955619","doi":"10.1158/1078-0432.ccr-13-0606","title":"<i>PIK3CA, BRAF</i>, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17","year":2013,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"","keywords":"PTEN; Cetuximab; Colorectal cancer; Medicine; Oncology; Internal medicine; Biomarker; Immunohistochemistry; Cancer; Tissue microarray; Cancer research; Biology","authors":[{"name":"Christos S. Karapetis","is_ca":false},{"name":"Derek J. Jonker","is_ca":false},{"name":"Manijeh Daneshmand","is_ca":false},{"name":"Jennifer Hanson","is_ca":false},{"name":"Christopher J. O’Callaghan","is_ca":false},{"name":"Celia Marginean","is_ca":true},{"name":"John Zalcberg","is_ca":false},{"name":"John Simes","is_ca":false},{"name":"Malcolm J. Moore","is_ca":false},{"name":"Niall C. Tebbutt","is_ca":false},{"name":"Timothy Price","is_ca":false},{"name":"Jeremy Shapiro","is_ca":false},{"name":"Nick Pavlakis","is_ca":false},{"name":"Peter Gibbs","is_ca":false},{"name":"Guy A. Van Hazel","is_ca":false},{"name":"Ursula Lee","is_ca":false},{"name":"Rashida Haq","is_ca":false},{"name":"Shakeel Virk","is_ca":false},{"name":"Dongsheng Tu","is_ca":false},{"name":"Ian A.J. Lorimer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1313937576986007,"gpt":0.4804904139291039,"spread":0.3490966562305032,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00234999,0.0005865308,0.001154144,0.0004057855,0.0001930237,0.0004704088,0.0004626889,0.0004815168,0.001516087],"category_scores_gemma":[0.001410015,0.0002158728,0.001035484,0.0004057352,0.0004455205,0.0001786421,0.0002813181,0.0008394087,0.0002176366],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001068987,"about_ca_system_score_gemma":0.001369865,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005374467,"about_ca_topic_score_gemma":0.01288071,"domain_scores_codex":[0.9991991,0.0004219521,0.00004305171,0.00009750049,0.0001530505,0.00008542161],"domain_scores_gemma":[0.9984263,0.0005255787,0.0002917708,0.0001220179,0.0000959323,0.0005384171],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5318089,0.003223703,0.3606223,0.000595373,0.004519213,0.0003580832,0.00008198713,0.002117335,0.01679877,0.00009379497,0.005371804,0.07440867],"study_design_scores_gemma":[0.05326794,0.04442246,0.8826119,0.0001261992,0.007216198,0.0006518558,0.00006477537,0.002752303,0.003890979,0.0001217984,0.004828198,0.00004543075],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936528,0.004335095,0.00008766913,0.0003793508,0.00003519025,0.00009595625,0.0006657794,0.00001126857,0.0007368463],"genre_scores_gemma":[0.9962632,0.001054587,0.0001960989,0.0002814918,0.0001018623,0.00005763003,0.001491922,0.000008508687,0.0005446073],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005374467,"threshold_uncertainty_score":0.01242805,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2140510616","doi":"10.1093/annonc/mdm399","title":"An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Essar Steel Algoma (Canada); Sault Area Hospital","funders":"Amgen","keywords":"Panitumumab; Medicine; Internal medicine; Colorectal cancer; Adverse effect; Refractory (planetary science); Oncology; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Progressive disease; Chemotherapy; Progression-free survival; Surgery; Cancer; Clinical trial; Cetuximab","authors":[{"name":"Eric Van Cutsem","is_ca":false},{"name":"Salvatore Siena","is_ca":false},{"name":"Yves Humblet","is_ca":false},{"name":"J.-L. Canon","is_ca":false},{"name":"Joan Maurel","is_ca":false},{"name":"Emilio Bajetta","is_ca":false},{"name":"Bart Neyns","is_ca":false},{"name":"Dusan Kotasek","is_ca":false},{"name":"Armando Santoro","is_ca":false},{"name":"Werner Scheithauer","is_ca":false},{"name":"Silvana Spadafora","is_ca":true},{"name":"R. G. Amado","is_ca":false},{"name":"N. Hogan","is_ca":false},{"name":"Marc Peeters","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08917227959175789,"gpt":0.4430520888022599,"spread":0.353879809210502,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002509715,0.001855309,0.004800146,0.000737242,0.0007815954,0.00116457,0.0008801164,0.001834152,0.003641697],"category_scores_gemma":[0.002324759,0.0009895774,0.002367074,0.0007299011,0.002058913,0.001854243,0.0005371578,0.004053652,0.000679318],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00116546,"about_ca_system_score_gemma":0.001426752,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001077334,"about_ca_topic_score_gemma":0.002155259,"domain_scores_codex":[0.9989707,0.0005443124,0.0000646066,0.0001757197,0.00008885748,0.0001556998],"domain_scores_gemma":[0.9978051,0.0006203798,0.0004115131,0.0002706289,0.0001306643,0.0007616951],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9686258,0.01289777,0.002379855,0.0002230287,0.0007439826,0.00005979903,0.00007492629,0.0004009749,0.004416016,0.00004384493,0.000248635,0.009885405],"study_design_scores_gemma":[0.648376,0.3399374,0.008774927,0.00001734322,0.0006411922,0.00009006976,0.00004299076,0.0007235018,0.0007970597,0.00008883732,0.0004819416,0.00002874989],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965944,0.0009963638,0.0002715584,0.0001463712,0.0001103771,0.0009078789,0.0003424419,0.00003501783,0.0005957097],"genre_scores_gemma":[0.9958732,0.0006091009,0.0006222111,0.0002861733,0.0002491555,0.0009906985,0.0005546673,0.00001219681,0.0008026338],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004800146,"threshold_uncertainty_score":0.01327276,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2114578638","doi":"10.1007/s00520-009-0744-x","title":"A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group","year":2010,"lang":"en","type":"article","venue":"Supportive Care in Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research","funders":"Robert H. Lurie Comprehensive Cancer Center; Amgen; Dermatology Foundation","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Grading (engineering); Pharmacovigilance; Adverse effect; Dermatology; MedDRA; Internal medicine","authors":[{"name":"Mario E. Lacouture","is_ca":false},{"name":"Michael L. Maitland","is_ca":false},{"name":"Siegfried Segaert","is_ca":false},{"name":"Ann Setser","is_ca":false},{"name":"Robert Baran","is_ca":false},{"name":"Lindy P. Fox","is_ca":false},{"name":"Joel B. Epstein","is_ca":false},{"name":"Andrei Barasch","is_ca":false},{"name":"Lawrence H. Einhorn","is_ca":false},{"name":"Lynne I. Wagner","is_ca":false},{"name":"Dennis P. West","is_ca":false},{"name":"Bernardo L. Rapoport","is_ca":false},{"name":"Mark G. Kris","is_ca":false},{"name":"Ethan Basch","is_ca":false},{"name":"Beth Eaby","is_ca":false},{"name":"Sandra Kurtin","is_ca":false},{"name":"Elise A. Olsen","is_ca":false},{"name":"Alice Chen","is_ca":false},{"name":"Janet Dancey","is_ca":true},{"name":"Andy Trotti","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01789740288903616,"gpt":0.3095338887530041,"spread":0.291636485863968,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005105558,0.0008957829,0.001506596,0.002022886,0.0005270562,0.0008014705,0.001032427,0.0005461414,0.003251683],"category_scores_gemma":[0.004919657,0.0001876617,0.003982168,0.001334769,0.0002394753,0.0006628617,0.0008019995,0.001380308,0.0005961373],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000998724,"about_ca_system_score_gemma":0.0008994366,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002222583,"about_ca_topic_score_gemma":0.00904151,"domain_scores_codex":[0.9969947,0.0009873759,0.0007053651,0.0001878063,0.0009607999,0.0001639181],"domain_scores_gemma":[0.996304,0.0008215507,0.00132224,0.0001413413,0.00120088,0.0002099867],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.02943028,0.002498125,0.5725697,0.005182787,0.01390447,0.0002649467,0.0002663589,0.006095675,0.005846549,0.001664342,0.05511424,0.3071625],"study_design_scores_gemma":[0.01027782,0.005573761,0.9438277,0.0004210245,0.004354943,0.0005871013,0.0001883534,0.004091151,0.001447235,0.00147429,0.02763858,0.000117982],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"methods","genre_scores_codex":[0.7347875,0.02555539,0.03383031,0.003632132,0.001660087,0.03067451,0.1000448,0.000812697,0.06900259],"genre_scores_gemma":[0.8463503,0.005867488,0.04108105,0.002144859,0.0004543688,0.02290077,0.06887321,0.0001439517,0.01218411],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.005105558,"threshold_uncertainty_score":0.02700108,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1488835948","doi":"10.1038/nrc1047","title":"Improving the evaluation of new cancer treatments: challenges and opportunities","year":2003,"lang":"en","type":"review","venue":"Nature reviews. Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; McGill University","keywords":"Clinical trial; Medicine; Cancer; Cancer drugs; Intensive care medicine; Computational biology; Biology; Internal medicine","authors":[{"name":"Mace L. Rothenberg","is_ca":false},{"name":"David P. Carbone","is_ca":false},{"name":"David H. Johnson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.3441167785904543,"gpt":0.471561718432465,"spread":0.1274449398420108,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01327794,0.001671155,0.005595669,0.004180157,0.0006506088,0.003921324,0.002696715,0.004176883,0.004924721],"category_scores_gemma":[0.0177296,0.0006449352,0.001368692,0.006099311,0.002241413,0.005495291,0.001835752,0.00448662,0.002123015],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002993476,"about_ca_system_score_gemma":0.007072262,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004063012,"about_ca_topic_score_gemma":0.009449077,"domain_scores_codex":[0.995353,0.002320282,0.0004837313,0.0002640509,0.001415626,0.0001632748],"domain_scores_gemma":[0.976162,0.01777361,0.001173979,0.0003862787,0.00393476,0.0005693168],"domain_codex":null,"domain_gemma":"evaluation","domain_candidate":"evaluation","domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001357876,0.00008247282,0.0002482252,0.01979664,0.0001751022,0.00009133221,0.00008459391,0.0003694306,0.0004620603,0.005031717,0.03468785,0.9388347],"study_design_scores_gemma":[0.0001412048,0.0002666845,0.001905268,0.03267015,0.0006219555,0.0009766163,0.0005371221,0.0002570071,0.000517295,0.01338523,0.9486631,0.0000583068],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003953592,0.9968836,0.0001578474,0.002215231,0.0002550084,0.000005215998,0.000007224202,0.000003957604,0.0004323995],"genre_scores_gemma":[0.0003673736,0.9983381,0.0003349266,0.0005295745,0.0003039112,0.000008412521,0.000008193012,0.000001140641,0.0001083617],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9867221,"threshold_uncertainty_score":0.07022136,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1484628085","doi":"10.1054/bjoc.1999.0964","title":"Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients","year":2000,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"","keywords":"Colorectal cancer; Immunohistochemistry; Medicine; Thymidylate synthase; Chemotherapy; Internal medicine; Hazard ratio; Oncology; Cancer; Immunostaining; Retrospective cohort study; Confidence interval; Gastroenterology; Pathology; Fluorouracil","authors":[{"name":"Angelo Paradiso","is_ca":false},{"name":"G. Simone","is_ca":false},{"name":"S. Petroni","is_ca":false},{"name":"B Leone","is_ca":false},{"name":"Carlos Vallejo","is_ca":false},{"name":"J. Lacava","is_ca":false},{"name":"A. Romero","is_ca":false},{"name":"M. Machiavelli","is_ca":false},{"name":"M. De Lena","is_ca":false},{"name":"Carmen J. Allegra","is_ca":false},{"name":"Patrick G. Johnston","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007577149139346323,"gpt":0.2761854846126583,"spread":0.268608335473312,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003111212,0.0001963855,0.0002803975,0.0004218499,0.0002111398,0.0003298208,0.000152896,0.0003461723,0.001165517],"category_scores_gemma":[0.001445715,0.0001349997,0.0002567064,0.0003033428,0.0002088893,0.0002149556,0.0001945095,0.0003390079,0.0002118637],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001140017,"about_ca_system_score_gemma":0.0001154507,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006647653,"about_ca_topic_score_gemma":0.0009874123,"domain_scores_codex":[0.9998289,0.00005422823,0.00001925996,0.00003278251,0.00003349135,0.00003125669],"domain_scores_gemma":[0.9990675,0.0003468511,0.0002732581,0.0000469801,0.00007357273,0.0001918576],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004042866,0.00001637844,0.9971145,0.000006432419,0.00002061651,0.0001421286,0.00001869296,0.00007211017,0.0009394944,0.000005521631,0.00002849053,0.001231291],"study_design_scores_gemma":[0.000007124722,0.0001565799,0.9984091,0.000002502494,0.00003120983,0.000639034,0.00003867947,0.0003703655,0.0002067451,0.00001321475,0.0001232994,0.000002240884],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99927,0.000358156,0.00008475947,0.00001926204,0.000004324058,0.000003646191,0.00004920725,0.000002722425,0.0002078318],"genre_scores_gemma":[0.9997663,0.00005373911,0.00003644057,0.000005221377,0.000007852401,0.000002674704,0.00005917219,6.600039e-7,0.0000679096],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001165517,"threshold_uncertainty_score":0.003899038,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1996283150","doi":"10.1016/j.ejca.2005.11.014","title":"Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?","year":2006,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hamilton Regional Laboratory Medicine Program","funders":"Bayer Corporation","keywords":"Sorafenib; Rash; Medicine; Toxicity; Internal medicine; Adverse effect; Pharmacology; Gastroenterology; Oncology; Surgery; Hepatocellular carcinoma","authors":[{"name":"Dirk Strumberg","is_ca":false},{"name":"Ahmad Awada","is_ca":false},{"name":"Holger W. Hirte","is_ca":true},{"name":"Jeffrey W. Clark","is_ca":false},{"name":"S. Seeber","is_ca":false},{"name":"Pr Piccart","is_ca":false},{"name":"Elke Hofstra","is_ca":false},{"name":"D. Voliotis","is_ca":false},{"name":"O. Christensen","is_ca":false},{"name":"Andreas Brueckner","is_ca":false},{"name":"Brian Schwartz","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02424993816082504,"gpt":0.335736719819994,"spread":0.3114867816591689,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007297767,0.00106304,0.007895984,0.001694883,0.0001502506,0.001096125,0.0008978966,0.0007888516,0.003024592],"category_scores_gemma":[0.0141029,0.0005804877,0.009642805,0.002125857,0.0002440131,0.0005979805,0.0005966375,0.0009250353,0.0002714604],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008879944,"about_ca_system_score_gemma":0.00133815,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001132776,"about_ca_topic_score_gemma":0.002474048,"domain_scores_codex":[0.9964059,0.001923208,0.0008720715,0.0002494493,0.000475252,0.00007409702],"domain_scores_gemma":[0.9918297,0.005046732,0.002173242,0.0002123157,0.0006248167,0.0001130762],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.05267776,0.000205971,0.008800752,0.2013137,0.4476356,0.0003524028,0.0001231298,0.001876775,0.001570481,0.0003015037,0.005545791,0.2795961],"study_design_scores_gemma":[0.01988574,0.007839197,0.03892814,0.0144324,0.8911728,0.0008581753,0.0001338542,0.001060346,0.001576907,0.0007752621,0.02324874,0.00008834215],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01889166,0.9779076,0.0008071219,0.0003297939,0.0002269067,0.0002264303,0.0009612816,0.00002624931,0.0006230115],"genre_scores_gemma":[0.2373036,0.7567635,0.001881414,0.0007773059,0.0004071093,0.0003687806,0.0016604,0.00002828546,0.0008096724],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007895984,"threshold_uncertainty_score":0.03859478,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2169034512","doi":"10.1186/1476-4598-13-135","title":"Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Damon Runyon Cancer Research Foundation; Gary Bennett Family Fund; National Cancer Institute; National Institutes of Health; Harvard University; Entertainment Industry Foundation","keywords":"KRAS; Microsatellite instability; Colorectal cancer; Biology; Oncology; Cancer research; Internal medicine; Hazard ratio; Cancer; Mutation; Genetics; Medicine; Allele; Gene; Microsatellite","authors":[{"name":"Yu Imamura","is_ca":false},{"name":"Paul Lochhead","is_ca":false},{"name":"Mai Yamauchi","is_ca":false},{"name":"Aya Kuchiba","is_ca":false},{"name":"Zhi Rong Qian","is_ca":false},{"name":"Xiaoyun Liao","is_ca":false},{"name":"Reiko Nishihara","is_ca":false},{"name":"Seungyoun Jung","is_ca":false},{"name":"Kana Wu","is_ca":false},{"name":"Katsuhiko Nosho","is_ca":false},{"name":"Yaoyu E. Wang","is_ca":false},{"name":"Shouyong Peng","is_ca":false},{"name":"Adam J. Bass","is_ca":false},{"name":"Kevin M. Haigis","is_ca":false},{"name":"Jeffrey A. Meyerhardt","is_ca":false},{"name":"Andrew T. Chan","is_ca":false},{"name":"Charles S. Fuchs","is_ca":false},{"name":"Shuji Ogino","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03177955794768534,"gpt":0.3868421815313034,"spread":0.3550626235836181,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002996056,0.0004639483,0.001965596,0.0114299,0.0003167055,0.001035211,0.0007140815,0.0005733485,0.001362707],"category_scores_gemma":[0.006833612,0.0004300583,0.00208275,0.01371128,0.00042999,0.0009832291,0.0004741302,0.0003384789,0.0002235148],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006434666,"about_ca_system_score_gemma":0.00287905,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002780169,"about_ca_topic_score_gemma":0.005307312,"domain_scores_codex":[0.9981626,0.0002978905,0.000897038,0.0003290562,0.000249069,0.00006435457],"domain_scores_gemma":[0.9893378,0.006678157,0.002260773,0.0002376702,0.001316025,0.0001695033],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.00108381,0.0001740215,0.1517204,0.3298919,0.01232494,0.002137007,0.0008327982,0.0003609465,0.003104661,0.0005498157,0.007860743,0.489959],"study_design_scores_gemma":[0.0002114991,0.0007909664,0.6258281,0.1531701,0.07612408,0.01477776,0.001878269,0.0004513342,0.001840107,0.0007823996,0.1239235,0.0002218661],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.01060899,0.9881368,0.0001227689,0.0001707308,0.00005688874,0.00003692601,0.0005988874,0.000006242214,0.0002619339],"genre_scores_gemma":[0.04020627,0.9580447,0.0004306101,0.0001570414,0.0001600667,0.00007655904,0.000835929,0.00000464437,0.00008421487],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.0114299,"threshold_uncertainty_score":0.01584488,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2079491773","doi":"10.1007/s10238-007-0145-8","title":"Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib","year":2007,"lang":"en","type":"review","venue":"Clinical and Experimental Medicine","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":146,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Sorafenib; Sunitinib; Medicine; Rash; Hematology; Pharmacology; Cancer; Internal medicine; Skin cancer; Dermatology; Oncology","authors":[{"name":"Camillo Porta","is_ca":true},{"name":"Chiara Paglino","is_ca":true},{"name":"Ilaria Imarisio","is_ca":true},{"name":"Lucia Bonomi","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2324804966332922,"gpt":0.4766617285255226,"spread":0.2441812318922304,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001131377,0.000634738,0.002042382,0.002177855,0.0003938235,0.001250558,0.001040909,0.0018021,0.002140139],"category_scores_gemma":[0.001523152,0.0003553454,0.0008103538,0.001939801,0.0008468154,0.002134425,0.0007163881,0.002799485,0.001057682],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007335872,"about_ca_system_score_gemma":0.001260207,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001155707,"about_ca_topic_score_gemma":0.003096767,"domain_scores_codex":[0.999708,0.00007177726,0.0000478794,0.00003808151,0.0001091604,0.00002508267],"domain_scores_gemma":[0.9993192,0.0004425387,0.0000823538,0.00002077454,0.00010223,0.00003295448],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001098512,0.00005837127,0.0002140366,0.01002237,0.0001963046,0.001463007,0.00009081688,0.0002861193,0.001263813,0.006237823,0.04223774,0.9378198],"study_design_scores_gemma":[0.00003736721,0.00008425884,0.0006055339,0.002563433,0.0001713922,0.006825468,0.0001105429,0.0001189469,0.0006586629,0.003525783,0.9852747,0.00002392532],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001665139,0.9977369,0.0001352035,0.001055517,0.0002213236,0.00000276027,0.000007097324,0.000005600018,0.0006690737],"genre_scores_gemma":[0.001103183,0.9972921,0.0002778139,0.0005746412,0.0002129803,0.000003722805,0.00001418375,0.000001460603,0.0005199242],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002177855,"threshold_uncertainty_score":0.007159472,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1510315517","doi":"10.1002/ijc.29025","title":"Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early‐onset fluoropyrimidine toxicity","year":2014,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"DPYD; Medicine; Toxicity; Internal medicine; Dihydropyrimidine dehydrogenase; Relative risk; Retrospective cohort study; Prospective cohort study; Gastroenterology; Pharmacogenetics; Surgery; Chemotherapy; Oncology; Fluorouracil; Confidence interval; Biology; Genetics; Genotype; Gene; Thymidylate synthase","authors":[{"name":"Tanja K. Froehlich","is_ca":false},{"name":"Ursula Amstutz","is_ca":true},{"name":"Stefan Aebi","is_ca":false},{"name":"Markus Joerger","is_ca":false},{"name":"Carlo R. Largiadèr","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03641762488755532,"gpt":0.3689768865698564,"spread":0.3325592616823011,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007351685,0.0003093846,0.0003318511,0.0004102462,0.0002139404,0.0004502223,0.000268172,0.0005277407,0.001410694],"category_scores_gemma":[0.004545391,0.0001721288,0.0002968269,0.0004205862,0.0002939594,0.0001795699,0.000221845,0.0005769735,0.0001751303],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001017535,"about_ca_system_score_gemma":0.0002168639,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001221902,"about_ca_topic_score_gemma":0.001258853,"domain_scores_codex":[0.9994621,0.0002160469,0.00005317587,0.0001272619,0.00009219741,0.00004925056],"domain_scores_gemma":[0.9965813,0.00181995,0.0008292112,0.0001995971,0.0001642887,0.0004057151],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001992418,0.00001173224,0.9965022,0.000004298814,0.00002683919,0.0002652282,0.0000206682,0.00009255588,0.0009455499,0.00001126555,0.00002816873,0.00189233],"study_design_scores_gemma":[0.00002433909,0.0001880675,0.9959473,0.000006789201,0.00007058094,0.002113426,0.00004852637,0.0009752774,0.0003539578,0.00007330792,0.0001919632,0.000006407554],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9991218,0.000353478,0.0001863441,0.00003635993,0.000004432385,0.000004868464,0.00006178247,0.000003546165,0.0002273588],"genre_scores_gemma":[0.9997278,0.00003918553,0.0001259508,0.00001031546,0.000008298168,0.000001464235,0.00004076333,0.000001705686,0.00004450438],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001410694,"threshold_uncertainty_score":0.004719257,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2147718573","doi":"10.1093/jnci/djp232","title":"Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial","year":2009,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"McMaster University; Niagara Health System; Ottawa Hospital; Health Sciences Centre; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Queen's University; Juravinski Cancer Centre; Dr. H. Bliss Murphy Cancer Centre; Sunnybrook Health Science Centre; University of Ottawa; Hamilton Health Sciences; Dalhousie University; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Cetuximab; Colorectal cancer; Medicine; Oncology; Clinical trial; Internal medicine; Cancer","authors":[{"name":"Nicole Mittmann","is_ca":true},{"name":"H. Au","is_ca":true},{"name":"D. Tu","is_ca":true},{"name":"Christopher J. O’Callaghan","is_ca":true},{"name":"Pierre K. Isogai","is_ca":true},{"name":"Christos S. Karapetis","is_ca":true},{"name":"John Zalcberg","is_ca":true},{"name":"W.K. Evans","is_ca":true},{"name":"M. J. Moore","is_ca":true},{"name":"J. Siddiqui","is_ca":true},{"name":"B. Findlay","is_ca":true},{"name":"Brian Colwell","is_ca":true},{"name":"John Simes","is_ca":true},{"name":"Peter Gibbs","is_ca":true},{"name":"Matthew Links","is_ca":true},{"name":"Niall C. Tebbutt","is_ca":true},{"name":"Derek J. Jonker","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2580697799418732,"gpt":0.5230566580323922,"spread":0.264986878090519,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01024914,0.00162832,0.00318464,0.0007672295,0.0007739655,0.001605315,0.00167183,0.001349767,0.003232369],"category_scores_gemma":[0.02115626,0.0005605013,0.005009232,0.001672958,0.0009422739,0.000637594,0.0007919386,0.002188805,0.0002130297],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.02311747,"about_ca_system_score_gemma":0.02757026,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.3949874,"about_ca_topic_score_gemma":0.43714,"domain_scores_codex":[0.9919096,0.005612715,0.0003260899,0.0004779668,0.001144166,0.0005295234],"domain_scores_gemma":[0.9883991,0.004091361,0.002986402,0.0006900153,0.00210145,0.001731544],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.845246,0.00243944,0.03236936,0.005184481,0.02638816,0.0002340545,0.0001342357,0.02263612,0.0006369435,0.001829586,0.01555011,0.04735151],"study_design_scores_gemma":[0.7215694,0.04633123,0.1321861,0.002247682,0.04389951,0.0003432447,0.0002030972,0.03903784,0.001040743,0.001631615,0.0112128,0.0002967489],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9021744,0.03993054,0.001947752,0.005287027,0.0004726724,0.009218524,0.02892589,0.0001344559,0.01190875],"genre_scores_gemma":[0.9775875,0.005703122,0.001827922,0.001026873,0.0001505524,0.0029733,0.009075851,0.00002552075,0.001629465],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3949874,"threshold_uncertainty_score":0.7853767,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}